Combinatorial optimization of mRNA structure, stability, and translation for RNA-based therapeutics
Open accessPublished version of a preprint
Abstract
Therapeutic mRNAs and vaccines are being developed for a broad range of human diseases, including COVID-19. However, their optimization is hindered by mRNA instability and inefficient protein expression. Here, we describe design principles that overcome these barriers. We develop a new RNA sequencing-based platform called PERSIST-seq to systematically delineate in-cell mRNA stability, ribosome load, as well as in-solution stability of a library of diverse mRNAs. We find that, surprisingly, in-cell stability is a greater driver of protein output than high ribosome load. We further introduce a method called In-line-seq, applied to thousands of diverse RNAs, that reveals sequence and structure-based rules for mitigating hydrolytic degradation. Our findings show that "superfolder" mRNAs can be designed to improve both stability and expression that are further enhanced through pseudouridine nucleoside modification. Together, our study demonstrates simultaneous improvement of mRNA stability and protein expression and provides a computational-experimental platform for the enhancement of mRNA medicines.
AI snapshot
Written from the paper’s full text.
TL;DR
The paper develops PERSIST-seq and In-line-seq to systematically optimize therapeutic mRNA stability, structure, and translation. It finds that in-cell mRNA stability is a greater driver of total protein output than high ribosome load, and that structure-optimized CDSs plus pseudouridine modification can improve both in-solution stability and protein expression.
Key findings
- In a 233-mRNA library, PERSIST-seq showed in-cell half-lives ranging from <5 h to >15 h; a model integrating ribosome load and in-cell stability predicted measured luciferase activity with r = 0.71, supporting in-cell stability as the dominant predictor of total protein output.
- In-solution stability was driven mainly by mRNA length and structure: the shortest MEV-encoding mRNAs had half-lives of 3.4 ± 0.6 h, while the longest eGFP-encoding mRNAs had half-lives of 1.1 ± 0.08 h; the ratio 3.0 ± 0.7 matched the inverse length ratio 958 nt/250 nt = 3.8.
- In-line-seq on 3,030 RNA fragments (2,165 after filtering) yielded DegScore, which predicted Nluc CDS in-solution half-lives with Pearson R = −0.63, p < 0.0001, outperforming dGMFE (R = −0.53) and summed unpaired probability (R = −0.60).
- Pseudouridine (ψ) or m1ψ substitution suppressed in-line hydrolysis and gave 1.2–2.7-fold stabilization for longer Nluc mRNAs; a RiboTree/LinearDesign/DegScore-optimized mRNA had t1/2 = 2.4 relative to Nluc start and 1.7-fold higher protein expression, and after 2 h accelerated degradation most ψ-modified optimized mRNA remained functional while the starting mRNA gave negligible activity.
Methods
- PERSIST-seq: pooled full-length IVT mRNA library of 233 constructs with varied 5′ UTRs, 3′ UTRs, and CDSs, barcoded and transfected into HEK293T cells; polysome sucrose-gradient fractionation and time-course sampling measured ribosome load, in-cell stability, and in-solution stability by barcode sequencing.
- In-line-seq: Eterna “Roll-your-own-structure” challenge generated 68-nt RNAs; 3,030 fragments were profiled by single-nucleotide-resolution in-line hydrolysis and SHAPE, then DegScore was trained as a windowed ridge regression model and validated against independent PERSIST-seq in-solution half-lives.
- Follow-up one-by-one assays used luciferase activity after transfection, capillary electrophoresis for in-solution half-lives, SHAPE/DMS chemical mapping, and ψ or m1ψ substitutions; design algorithms included LinearDesign, GC-rich codon sampling, RiboTree, and Eterna participant designs.
Limitations
- Stated: experiments were limited to HEK293T cells, so optimal UTRs are likely cell-type dependent; the study focused on naked, non-formulated mRNAs, and formulated mRNA libraries may reveal additional effects; DegScore was trained on unmodified nucleotides and does not account for ψ stabilization; blinding and randomization were not used.
- Evident from the text: the main pooled library contained 233 constructs, with some design rules derived from Eterna-designed subsets and accelerated degradation conditions (pH 10 with Mg2+), and the protein-output model assumes first-order translation and decay kinetics with negligible Nluc protein degradation.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
16 of 29 cited sources checked · 2 supported · 1 flagged · accuracy not yet measured
- Interpretationcitation
Independent of the nucleotide identity 5' of the U, the bond leading to 3' U is a hotspot for in-line nucleophilic attack.
“Thus, independent of the nucleotide identity 5’ of the U, this bond is a hotspot for in-line nucleophilic attack63,65.”
Quote in the paperSubstantial claim2 of 2 sources checked- cites [63] Kaukinen, U., Lyytikäinen, S., Mikkola, S. & Lönnberg, H. The reactivity of phosphodiester bonds within linear single-stranded oligoribonucleotides is strongly dependent on the base sequence. Nucleic Acids Res. 30, 468–474 (2002). source
The Results (page unavailable) report that cleavage of the studied 5′-UpA-3′ bond varies strongly with the surrounding sequence; in one sequence, no reaction was detected in three months. The Discussion (page unavailable) explicitly rejects the idea that this bond is inherently prone to cleavage. The paper studies a bond following U, rather than establishing that a bond leading to 3′ U is a hotspot independent of the preceding nucleotide. (LLM, conf=0.82)
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measured - cites [65] Seetin, M. G., Kladwang, W., Bida, J. P. & Das, R. Massively parallel RNA chemical mapping with a reduced bias MAP-seq protocol. Methods Mol. Biol. 1086, 95–117 (2014). source
The Introduction (page unavailable) discusses chemical probing and nucleotide reactivity, and the References list a work on in-line probing. Neither passage addresses whether the bond leading to a 3′ U is a hotspot for in-line nucleophilic attack regardless of the 5′ nucleotide; searches for that mechanism and sequence preference found no supporting passage in our copy. (LLM, conf=0.73)
Experimental — accuracy not yet measured
- Findingown data
Highly structured 5' UTRs, such as dengue virus (DEN2), can support efficient translation, contrary to previous reports.
“Most surprising, in contrast to previous reports47–49, we found 5’ UTRs that are highly structured, such as the dengue virus (DEN2), can support efficient translation.”
Quote in the paperSubstantial claim1 of 3 sources checked- cites [47] Zhang, H. et al. LinearDesign: efficient algorithms for optimized mRNA sequence design. Preprint at https://arxiv.org/abs/2004.10177 (2020). source
Checked before — its earlier verdict is held back until a new check runs.
- cites [48] Ding, Y. et al. In vivo genome-wide profiling of RNA secondary structure reveals novel regulatory features. Nature 505, 696–700 (2014). source
- cites [49] Shah, P., Ding, Y., Niemczyk, M., Kudla, G. & Plotkin, J. B. Rate-limiting steps in yeast protein translation. Cell 153, 1589–1601 (2013). source
- Findingown data
PERSIST-seq data across different CDS types confirmed the effect of CDS length on RNA stability.
“The strongest prediction of previous theoretical modeling7 was that length changes should drive the most variation in in-solution stability, and PERSIST-seq data across different different CDS types confirmed the effect of CDS length on RNA stability, (Fig. 2G).”
Quote in the paperSubstantial claim1 of 1 sources checked- cites [7] Wayment-Steele, H. K. et al. Theoretical basis for stabilizing messenger RNA through secondary structure design. Nucleic Acids Res. 49, 10604–10617 (2021). source
- The authors state this as an assumption: The high pH buffer containing Mg2+ mimics the high effective pH and positively charged environment that can arise in lipid nanoparticles, protamine, and other formulations for mRNA therapeutics.
- Premisecitation
Nluc protein has negligible degradation as measured by luciferase activity in transiently Nluc-expressing HEK293 cells for at least 6 hours after cycloheximide treatment.
“kp is set to 0 since Nluc protein has negligible degradation as measured by luciferase activity in transiently Nluc-expressing HEK293 cells for at least 6 hours after cycloheximide treatment, which allows assessment of protein degradation in the absence of further translation91.”
Quote in the paperSubstantial claim1 of 1 sources checked- cites [91] Martin, M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet J. 17, 10 (2011). source
The Introduction and Algorithm sections describe adapter trimming in sequencing reads, not protein degradation experiments. Searches for Nluc, HEK293, luciferase activity, and cycloheximide found no passage addressing the claimed six-hour stability. (LLM, conf=0.78)
Experimental — accuracy not yet measured
- Interpretationcitation
The effect of high translation efficiency on stability may derive from overcrowding of ribosomes on mRNA coding regions due to rapid initiation, which can induce sterical ribosome collisions that lead to translation-dependent mRNA decay.
“This effect may derive from overcrowding of ribosomes on mRNA coding regions due to rapid initiation, which can induce sterical ribosome collisions that have recently been found to lead to translation-dependent mRNA decay78,79.”
Quote in the paperSubstantial claim1 of 2 sources checked- cites [78] Yoffe, A. M. et al. Predicting the sizes of large RNA molecules. Proc. Natl Acad. Sci. USA 105, 16153–16158 (2008). source
- cites [79] Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 2603–2615 (2020). source
The Methods and Discussion describe BNT162b2 vaccine efficacy and safety, not how translation efficiency affects mRNA stability. Searches for ribosome collisions, rapid initiation, and translation-dependent mRNA decay found no passage addressing the claimed mechanism. (LLM, conf=0.76)
Experimental — accuracy not yet measured
- Findingown data
112 of the mRNAs in the library contained varied 5' and/or 3' UTRs.
“112 of these mRNAs contained varied 5’ and/or 3’ UTRs (Fig. 1A).”
Quote in the paperNot a substantial claim - Findingown data
Chimeric fusion of the hHBB 5' UTR with TEV or 5' TOP sequence increased polysome loading.
“Moreover, the chimeric fusion of the hHBB 5’ UTR with elements such as the TEV or 5’ TOP sequence in the same 5’ UTR increased polysome loading.”
Quote in the paperSubstantial claim - Findingown data
The mRNA designs with highest ribosome load were observed across 5' UTRs of cellular as well as viral origins.
“Overall, the mRNA designs with highest ribosome load were observed across 5’ UTRs of cellular as well as viral origins (Fig. 1E, Table S1).”
Quote in the paperSubstantial claim - Findingown data
One-by-one tests of the 5' UTRs selected to have high ribosome load gave lower total protein output than the starting sequence.
“Interestingly, one-by-one tests of the 5’ UTRs selected to have high ribosome load gave lower total protein output than the starting sequence (see Supplemental Text); this observation foreshadowed a tradeoff between ribosome load and mRNA stability that we dissect in greater detail below.”
Quote in the paperSubstantial claim - Findingown data
The integrated model accurately predicts protein output for a given mRNA based on its ribosome load and in-cell stability.
“We integrate our datasets to develop a model that accurately predicts protein output for a given mRNA based on its ribosome load and in-cell stability.”
Quote in the paperSubstantial claim- The authors state this as an assumption: Translation follows first-order kinetics and mRNA and protein decay are exponential.
- Findingown data
Specific 5' UTRs (mouse COL1A2, Hoxa9 P4, Rpl18a TOP, plant RBCS1A, poxvirus poly(A) leader fused to scrambled 5' UTR, TEV, TMV) had higher ribosome load (1.7-2.3) than the hHBB 5' UTR (1.57).
“All of these sequences had a higher ribosome load (1.7–2.3) than the hHBB 5’ UTR (1.57), thereby identifying potential UTR design strategies to boost mRNA translational efficiency.”
Quote in the paperSubstantial claim - Findingown data
Mutation of the uORF in the SARS-CoV-2 5' UTR (AUG to UUG; CoV2-UUG) resulted in higher ribosome load than the wildtype 5' UTR.
“We first observed that mutation of the uORF in the 5’ UTR (AUG mutated to UUG; CoV2-UUG) resulted in higher ribosome load than the wildtype 5’ UTR (Fig. 1F–G).”
Quote in the paperSubstantial claim - Findingown data
Deletion of SL1 from the SARS-CoV-2 5' UTR increased ribosome load from 1.23 (CoV-2) to 1.5 (CoV-2-UUG-dSL-1), almost reaching the hHBB level (1.57).
“In particular, deletion of SL1 from the SARS-CoV-2 5’ UTR increased ribosome load from 1.23 (CoV-2) to 1.5 (CoV-2-UUG-dSL-1) which almost reaches the level of ribosome load of hHBB (1.57) (Fig. 1G).”
Quote in the paperSubstantial claim - Findingown data
The most impactful effects of sequence k-mers were at the 5' and 3' end of the randomized 5' UTR stretch.
“We found the most impactful effects of sequence k-mers at the 5’ and 3’ end of the randomized 5’ UTR stretch (Fig. S2E, Table S3).”
Quote in the paperNot a substantial claim - Findingown data
The mRNA library contained 233 different mRNA sequences in total.
“Our mRNA library contained 233 different mRNA sequences in total (Table S1).”
Quote in the paperSubstantial claim - Findingown data
The largest variation in ribosome load was observed for the 5' UTR variants group.
“The largest variation in ribosome load was observed for the 5’ UTR variants group (Fig. 1D).”
Quote in the paperSubstantial claim - Findingown data
At 24 hours, 6 of 8 RiboTree-optimized mRNA designs demonstrated higher luciferase activities than the Nluc reference mRNA.
“6 of 8 RiboTree-optimized mRNA designs demonstrated higher luciferase activities than the Nluc reference mRNA at 24 hours”
Quote in the paperSubstantial claim - Findingown data
RNA sequence in a given structure can dramatically affect degradation of the structure motif.
“When analyzed across known secondary structure motifs, the data revealed that the RNA sequence in a given structure can dramatically affect degradation of the structure motif.”
Quote in the paperSubstantial claim - Findingown data
The majority of the mRNA stabilized with ψ and a structure-optimized CDS remains functional after 2 hours of accelerated solution degradation.
“the majority of the mRNA stabilized with ψ and a structure-optimized CDS remains functional after 2 hours of accelerated solution degradation”
Quote in the paperSubstantial claim - Findingown data
Hydrolysis is suppressed in symmetric internal loops compared to asymmetric internal loops.
“A particularly salient characteristic was suppressed hydrolysis in symmetric internal loops compared to asymmetric internal loops (Fig. 3C).”
Quote in the paperSubstantial claim - Findingown data
PERSIST-seq confirms predictions that extremely highly structured mRNAs can exhibit more than double the in-solution half-lives of conventionally designed mRNAs.
“PERSIST-seq confirms predictions that extremely highly structured mRNAs can exhibit more than double the in-solution half-lives of conventionally designed mRNAs”
Quote in the paperSubstantial claim - Findingown data
Within mRNAs encoding for a single protein (Nluc, eGFP, or MEV), the variance in in-solution half-lives was greater than for the variance across UTR variants.
“Within mRNAs encoding for a single protein (Nluc, eGFP, or MEV), the variance in in-solution half-lives was greater than for the variance across UTR variants (Fig. 2G), and these values correlated well with different metrics for predicted structure (see below).”
Quote in the paperSubstantial claim- The authors state this as an assumption: The high pH buffer containing Mg2+ mimics the high effective pH and positively charged environment that can arise in lipid nanoparticles, protamine, and other formulations for mRNA therapeutics.
- Findingown data
The effect of uridine susceptibility can be alleviated through inclusion of the nucleoside modification ψ or m1ψ.
“this effect can be alleviated through inclusion of the nucleoside modification ψ or m1ψ”
Quote in the paperSubstantial claim - Findingreasoning
There is a 'sweet spot' for translation efficiency for maximal total protein output.
“there is a ‘sweet spot’ for translation efficiency for maximal total protein output.”
Quote in the paperSubstantial claim - Findingown data
Rules for hydrolytic degradation depended on the type of RNA structural loop in which a nucleotide appears.
“In addition, we noted rules for hydrolytic degradation that depended on the type of RNA structural loop in which a nucleotide appears.”
Quote in the paperSubstantial claim - Findingown data
ψ and m1ψ substitutions did not change the global structure of the RNAs.
“Structure mapping data based on SHAPE and DMS profiling confirmed that ψ and m1ψ substitutions did not change the global structure of the RNAs; the suppression of in-line hydrolysis appears to be due to local chemical or structural effects.”
Quote in the paperSubstantial claim - Findingown data
At 24 hours, 6 of 8 Eterna-derived designs tested had lower luciferase activity than the Nluc reference mRNA.
“At 24 hours, the trend of lower luciferase activity continued for 6 of 8 Eterna-derived designs tested compared to the Nluc reference mRNA”
Quote in the paperNot a substantial claim - Findingown data
For six constructs from the 233x-mRNA library, uniform substitution of U with ψ led to 1.2-2.7-fold stabilization of in-solution degradation lifetimes for longer Nluc-encoding mRNAs.
“Consistent with our in-line hydrolysis data on small RYOS RNAs, we observed a 1.2–2.7-fold stabilization for these longer Nluc-encoding mRNAs when U was uniformly substituted with ψ (Fig. S5C).”
Quote in the paperSubstantial claim - Findingown data
PERSIST-seq gives a wide dynamic range of in-cell half-lives, ranging from less than 5 hours to over 15 hours.
“For our library of 233 mRNAs, PERSIST-seq gives a wide dynamic range of in-cell half-lives, ranging from less than 5 hours to over 15 hours (Fig. 2A).”
Quote in the paperSubstantial claim - Findingown data
At 6 hours, most vendor-derived and GC-rich designs had slightly higher luciferase activities than the reference Nluc sequence.
“whereas most vendor-derived and GC-rich designs had slightly higher activities (Fig. 4C).”
Quote in the paperNot a substantial claim - Findingown data
RNA structure was a dominant predictor of in-line hydrolysis rate.
“At a broad level, the data confirmed that RNA structure was a dominant predictor of in-line hydrolysis rate (compare, e.g., SHAPE to in-line data; Fig. S4A), but a closer look revealed additional sequence and structure dependent rules for in-line hydrolysis.”
Quote in the paperSubstantial claim - Findingown data
Highly structured CDSs can strongly affect both the in-solution stability of mRNAs and their protein synthesis in cells.
“Moreover, using our RNA degradation predictor DegScore and Eterna-derived designs, we saw that the highly structured CDSs can strongly affect both the in-solution stability of mRNAs and their protein synthesis in cells (Fig. 2, Fig. 3).”
Quote in the paperSubstantial claim - Findingown data
In cells, modulation of UTR sequence produced large variation in in-cell stability.
“For example, in cells, modulation of UTR sequence produced large variation in in-cell stability (Fig. 2A), presumably through changes in recruitment of cellular machinery that affect mRNA decay.”
Quote in the paperSubstantial claim- The authors state this as an assumption: The high pH buffer containing Mg2+ mimics the high effective pH and positively charged environment that can arise in lipid nanoparticles, protamine, and other formulations for mRNA therapeutics.
- Findingown data
In aqueous solution without cellular machinery, changing the UTRs produced comparably little change in RNA stability to hydrolytic degradation of the CDS.
“In contrast, in aqueous solution without such cellular machinery, changing the UTRs produced comparably little change in RNA stability to hydrolytic degradation of the CDS (Fig. 2G).”
Quote in the paperSubstantial claim- The authors state this as an assumption: The high pH buffer containing Mg2+ mimics the high effective pH and positively charged environment that can arise in lipid nanoparticles, protamine, and other formulations for mRNA therapeutics.
- Findingown data
The widest in-cell stability variation was observed in the CDS and 5' UTR variant groups.
“However, surprisingly, we instead observed the widest in-cell stability variation in the CDS and 5’ UTR variant groups (Fig. 2A).”
Quote in the paperSubstantial claim - Findingown data
DegScore gave the highest accuracy in predicting in-solution stability over all measured mRNAs, including low and high structure eGFP mRNAs from Moderna, Eterna, and Ribotree.
“Beyond the Nluc CDS variants, we confirmed that DegScore gave the highest accuracy in predicting in-solution stability when evaluated over all the measured mRNAs, including low and high structure eGFP mRNAs from Moderna researchers, Eterna, and Ribotree (Table S1 and Fig. S5A,B).”
Quote in the paperSubstantial claim - Findingown data
For the most-sampled triloop secondary structure, in-line hydrolysis rates varied by up to 100-fold depending on sequence.
“For example, in the case of the most-sampled secondary structure of triloops, the in-line hydrolysis rates varied by up to 100-fold depending on sequence (Fig. S4B).”
Quote in the paperSubstantial claim - Findingown data
DegScore correlated moderately with 24 hour protein expression (R = −0.47, p = 0.02).
“and moderately with 24 hour protein expression (R = −0.47, p = 0.02)”
Quote in the paperSubstantial claim - Findingown data
The largest changes in in-solution stability occurred across CDS variants.
“The largest changes in in-solution stability occurred across CDS variants.”
Quote in the paperSubstantial claim- The authors state this as an assumption: The high pH buffer containing Mg2+ mimics the high effective pH and positively charged environment that can arise in lipid nanoparticles, protamine, and other formulations for mRNA therapeutics.
- Findingown data
Both Nluc start and LinearDesign-1 CDSs with hHBB UTRs maintained high protein expression at 6 and 24 hours.
“Importantly, both Nluc start and LinearDesign-1 CDSs with hHBB UTRs maintained high protein expression at 6 and 24 hours (Fig. 4A) indicating that, despite ψ modification and highly structured CDSs, translation is sustained.”
Quote in the paperSubstantial claim - Findingown data
The shortest mRNAs in the pool, encoding MEV, exhibited in-solution half-lives of 3.4±0.6 hours.
“The shortest mRNAs in the pool, encoding a multi-epitope SARS-CoV-2 vaccine CDS (MEV), exhibited in-solution half-lives of 3.4±0.6 hours.”
Quote in the paperSubstantial claim- The authors state this as an assumption: The high pH buffer containing Mg2+ mimics the high effective pH and positively charged environment that can arise in lipid nanoparticles, protamine, and other formulations for mRNA therapeutics.
- Findingown data
The results for in-solution stability were strikingly different from the results for in-cell stability across the mRNA library.
“The results for in-solution stability were strikingly different from the results for in-cell stability across the mRNA library.”
Quote in the paperSubstantial claim- The authors state this as an assumption: The high pH buffer containing Mg2+ mimics the high effective pH and positively charged environment that can arise in lipid nanoparticles, protamine, and other formulations for mRNA therapeutics.
- Findingown data
Ribotree_LinearDesign_degscoreall_1 mRNA had an in-solution half-life of 2.4 relative to Nluc start.
“yielded an mRNA that was both highly stable in solution (t1/2 = 2.4, relative to Nluc start)”
Quote in the paperSubstantial claim - Findingown data
Preparation of mRNAs with ψ substituted for U led to increased in-solution stability across both Nluc start and LinearDesign-1 CDSs, independent of UTR.
“As expected, preparation of mRNAs with ψ substituted for U led to increased in-solution stability across both these CDSs, independent of UTR (Fig. S6).”
Quote in the paperSubstantial claim - Findingown data
RNA linkages 5' of a uridine residue are particularly susceptible to degradation.
“RNA linkages 5’ of a uridine residue are particularly susceptible to degradation”
Quote in the paperSubstantial claim - Findingown data
Unstable mRNAs include 5' UTR or 5'/3' UTR variants that were heavily polysome shifted.
“More specifically, these unstable mRNAs include 5’ UTR or 5’/3’ UTR variants that were heavily polysome shifted (Fig. 2B, polysome/monosome ratio).”
Quote in the paperSubstantial claim - Findingown data
Increased association to monosomes and thus a more moderate increase in overall ribosome load is positively associated with mRNA stability.
“Increased association to monosomes and thus a more moderate increase in overall ribosome load is positively associated with mRNA stability (Fig. 2B, monosomes/pre-polysome(pre-80S) ratios).”
Quote in the paperSubstantial claim - Findingown data
DegScore was uncorrelated with 6 hour protein expression.
“yet was uncorrelated with 6 hour protein expression (Fig. 4E).”
Quote in the paperSubstantial claim - Findingown data
The largest spread of in-solution half-lives (2.8-fold) occurred in the CDS variants for Nluc mRNAs.
“The largest spread of in-solution half-lives (2.8-fold) occurred in the CDS variants for Nluc mRNAs.”
Quote in the paperNot a substantial claim- The authors state this as an assumption: The high pH buffer containing Mg2+ mimics the high effective pH and positively charged environment that can arise in lipid nanoparticles, protamine, and other formulations for mRNA therapeutics.
- Findingown data
By 24 hours, mRNA with LinearDesign-1 CDS displayed a two-fold increase in luciferase yield compared to Nluc start.
“Indeed, by 24 hours, the mRNA with the LinearDesign-1 CDS displayed an outstanding two-fold increase in luciferase yield compared to that of Nluc start (Fig. 4A).”
Quote in the paperSubstantial claim - Findingown data
The optimized Ribotree_LinearDesign_degscoreall_1 mRNA exhibited higher resistance to degradation in-solution than Nluc Start mRNA.
“the optimized Ribotree_LinearDesign_degscoreall_1 mRNA exhibited higher resistance to degradation in-solution than the Nluc Start mRNA”
Quote in the paperSubstantial claim - Findingown data
Substitution of U with either ψ or m1ψ led to suppression of in-line hydrolysis at nucleotides 1 to 2 positions 5' of the substitution.
“We also observed suppression of in-line hydrolysis at nucleotides 1 to 2 positions 5′ of the substitution (Fig. 3F), possibly due to locally enhanced base stacking72.”
Quote in the paperSubstantial claim - Findingown data
Eterna-derived designs exhibited up to 2.6-fold higher in-solution half-life compared to the Nluc start reference sequence.
“Compared to the Nluc start reference sequence, designs originating from Eterna exhibited up to 2.6-fold higher in-solution half-life (see, e.g., RLT-10)”
Quote in the paperSubstantial claim - Findingreasoning
Combining optimal UTRs, DegScore optimization with RiboTree, and ψ modification achieves improved protein expression.
“By combining optimal UTRs, DegScore optimization with RiboTree, and ψ modification, we are able to achieve high mRNA stability and improved protein expression.”
Quote in the paperSubstantial claim - Findingown data
6 hour protein expression correlated strongly with Maximum Ladder Distance (R = −0.55, p<0.001).
“and the “Maximum Ladder Distance73,” or the maximum helix path length (R = −0.55, p<0.001)”
Quote in the paperSubstantial claim - Findingown data
The UTR combinations that outperform hHBB include multiple cellular 5' UTRs and the dengue virus 5' and 3' UTRs.
“include multiple cellular 5’ UTRs as well as, unexpectedly, the dengue virus 5’ and 3’ UTRs”
Quote in the paperSubstantial claim - Findingown data
DegScore accuracy outperformed dGMFE (R = -0.53) and SUP (R = -0.60) in predicting in-solution half-lives for Nluc CDS variants.
“Strikingly, the accuracy of DegScore outperformed the accuracy of two other metrics that have been used in prior studies to parametrize RNA structure but do not take into sequence or structure-motif dependences of RNA hydrolysis: the free energy of the predicted minimum free energy secondary structure, the metric used in several design algorithms including LinearDesign (dGMFE; R = −0.53), and the”
Quote in the paperSubstantial claim - Findingown data
DegScore regression coefficients with the largest magnitude corresponded to the identity of the nucleotide 3' of a linkage.
“The DegScore regression coefficients with the largest magnitude corresponded to the identity of the nucleotide 3’ of a linkage (Fig. 3D).”
Quote in the paperSubstantial claim - Findingreasoning
High translation efficiency mRNAs associated with the heaviest polysomes tend to be less stable.
“high translation efficiency mRNAs associated with the heaviest polysomes tend to be less stable”
Quote in the paperSubstantial claim - Findingown data
LinearDesign-1 CDS mRNAs exhibited a particularly long in-solution half-life.
“LinearDesign-1 CDS mRNAs also exhibited a particularly long in-solution half-life (Fig. 3G–H).”
Quote in the paperSubstantial claim - Findingown data
mRNAs designed to have highly structured CDSs by the LinearDesign algorithm exhibited polysome fraction profiles dominated by 80S monosomes.
“We did note that mRNAs designed to have highly structured CDSs by the LinearDesign algorithm exhibited polysome fraction profiles dominated by 80S monosomes (Fig. 1E), further discussed below.”
Quote in the paperNot a substantial claim - Findingown data
DegScore predictions strongly correlate with in-solution half-lives for Nluc CDS variants with the widest variance (Pearson R = -0.63, p<0.0001).
“For the Nluc CDS variants that showed the widest variance in in-solution half-lives, we observed a strong correlation of DegScore predictions to the in-solution half-lives (Pearson R = −0.63, p<0.0001).”
Quote in the paperSubstantial claim - Findingown data
Designs from the LinearDesign server and modifications from Eterna participants and the RiboTree algorithm produced constructs with increased half-life up to approximately 2.5-fold over the Nluc reference sequence.
“Designs from the LinearDesign server and modifications to these designs from both Eterna participants (e.g., AB_rhiju_mod3) and the RiboTree algorithm produced constructs with increased half-life up to approximately 2.5-fold over the Nluc reference sequence”
Quote in the paperSubstantial claim - Findingown data
Chemical structure mapping showed that the long-lived LinearDesign-1 was significantly more highly structured than Yellowstone, as assessed by DMS and SHAPE reactivities.
“Chemical structure mapping showed that the long-lived LinearDesign-1 was significantly more highly structured than Yellowstone, as assessed by dimethyl sulfate (DMS) and selective 2’-hydroxyl acylation with primer extension (SHAPE) reactivities59,60 (Fig. 2H, Fig. S3) and structure models guided by these data (Fig. 2I).”
Quote in the paperSubstantial claim0 of 2 sources checked- cites [59] Leonhardt, C. et al. Single-cell mRNA transfection studies: delivery, kinetics and statistics by numbers. Nanomedicine 10, 679–688 (2014). source
Checked before — its earlier verdict is held back until a new check runs.
- cites [60] Wang, H. et al. Diversity of putative archaeal RNA viruses in metagenomic datasets of a yellowstone acidic hot spring. Springerplus 4, 189 (2015). source
Checked before — its earlier verdict is held back until a new check runs.
- The authors state this as an assumption: The high pH buffer containing Mg2+ mimics the high effective pH and positively charged environment that can arise in lipid nanoparticles, protamine, and other formulations for mRNA therapeutics.
- Findingown data
In many RNA loop types, linkages that lead to a 3' uridine were particularly prone to degradation.
“Furthermore, in many RNA loop types, it appeared that linkages that lead to a 3’ uridine were particularly prone to degradation (Fig. 3C, Fig. S4C), and this effect was reproduced in follow-up experiments using capillary electrophoresis readouts (Fig. S4D).”
Quote in the paperSubstantial claim - Findingown data
PERSIST-seq identifies previously unknown tradeoffs and additive effects between different tunable aspects of mRNA performance as key determinants.
“This technology identifies previously unknown tradeoffs and additive effects between different tunable aspects of mRNA performance as key determinants.”
Quote in the paperSubstantial claim - Findingown data
RiboTree's computational modifications from the starting LinearDesign solution are characterized by reducing Us in loops and shifting local base-pairing to minimize overall loop size, even if resulting in additional smaller loops.
“These computational modifications are characterized by reducing the presence of Us in loops, and shifting local base-pairing to minimize the overall size of loops, even if such shifts result in additional smaller loops.”
Quote in the paperSubstantial claim - Findingown data
mRNAs with longer UTRs had consistently reduced in-solution half-life to hydrolytic degradation across all 6 CDSs.
“In terms of in-solution stability, we expected the mRNAs with the longer UTRs to have consistently reduced half-life to hydrolytic degradation across all 6 CDSs, and capillary electrophoresis experiments confirmed this expectation (Fig. S6).”
Quote in the paperSubstantial claim - Findingown data
Substitution of U with either ψ or m1ψ led to remarkable suppression of in-line hydrolysis at the substituted residues.
“We observed that substitution of U with either ψ or m1ψ led to remarkable suppression of in-line hydrolysis at the substituted residues, presumably through changed nucleophilicity at the site of substitution (Fig. 3F).”
Quote in the paperSubstantial claim - Findingown data
Selected CDS designs support a range of observed in-solution half-lives from 0.69- to 1.8-fold relative to Nluc start.
“The selected CDS designs represented CDSs from diverse origins that support a range of observed in-solution half-lives (from 0.69- to 1.8-fold relative to our reference ‘Nluc start’ sequence; Fig. 2G).”
Quote in the paperNot a substantial claim - Findingnone given
PERSIST-seq enables massively parallel evaluation of the effects of UTR and CDS sequence and structure on in-cell mRNA translation efficiency, in-cell mRNA stability, and in-solution stability.
“Our first set of experimental findings derive from the integrated PERSIST-seq technology, which enables massively parallel evaluation of the effects of UTR and CDS sequence and structure on in-cell mRNA translation efficiency, in-cell mRNA stability, and in-solution stability.”
Quote in the paperSubstantial claim - Findingown data
6 hour protein expression correlated strongly with the predicted number of hairpins (R = 0.70, p<0.001).
“6 hour protein expression correlated strongly with the predicted number of hairpins (R = 0.70, p<0.001)”
Quote in the paperSubstantial claim - Findingown data
DegScore quantitatively captured features like increased hydrolysis rates at linkages leading to 3' U.
“To distill these observations into a predictive model, we trained a windowed ridge regression model called ‘DegScore’ based on these In-line-seq data (Fig. 3D; see Methods) which quantitatively captured features like the increased hydrolysis rates at linkages leading to 3’ U (Fig. 3D).”
Quote in the paperSubstantial claim - Findingown data
The dengue virus 3' UTR individually increases ribosome loading.
“the dengue virus 5’ and 3’ UTRs, which both individually increase ribosome loading”
Quote in the paperSubstantial claim - Findingown data
Less variance in ribosome loading was observed among CDS variants than for UTR variants.
“As noted above, we observed less variance in ribosome loading among CDS variants than for UTR variants (Fig. 1D–E).”
Quote in the paperSubstantial claim - Findingown data
Designs from commercial algorithms or optimized GC-content tended to exhibit similar in-solution half-lives to the Nluc start reference sequence.
“while designs from commercial algorithms or optimized GC-content tended to exhibit similar in-solution half-lives (Fig. 4C).”
Quote in the paperSubstantial claim - Findingown data
Incorporation of ψ into either mRNA further enhanced in-solution stability, with a readout based on mRNA function in cells.
“incorporation of ψ into either mRNA further enhanced in-solution stability, this time with a readout based on mRNA function in cells (Fig 4G).”
Quote in the paperSubstantial claim - Findingreasoning
The longest mRNAs, encoding eGFP, exhibited much shorter in-solution half-lives of 1.1±0.08 hours.
“The longest mRNAs, encoding eGFP, exhibited much shorter in-solution half-lives of 1.1±0.08 hours (Fig. 2G), as expected given the larger number of sites of potential hydrolysis.”
Quote in the paperSubstantial claim- The authors state this as an assumption: The high pH buffer containing Mg2+ mimics the high effective pH and positively charged environment that can arise in lipid nanoparticles, protamine, and other formulations for mRNA therapeutics.
- Findingown data
The starting mRNA sequence gives negligible in-cell activity after 2 hours of accelerated solution degradation.
“whereas our starting mRNA sequence gives negligible in-cell activity after the same degradation (Fig 4G).”
Quote in the paperSubstantial claim - Findingown data
mRNAs harboring highly structured 5' and 3' UTRs can support high levels of protein synthesis in cells.
“Thus far we found that mRNAs harboring highly structured 5’ and 3’ UTRs can support high levels of protein synthesis in cells.”
Quote in the paperSubstantial claim - Findingown data
Constructs with higher ribosome load values tended to be more unstable.
“We also noted that constructs with higher ribosome load values tended to be more unstable (Fig. 2B).”
Quote in the paperSubstantial claim - Findingown data
The next largest source of variation in in-solution stability was driven by differences in mRNA structure.
“The next largest source of variation in in-solution stability was driven by differences in mRNA structure.”
Quote in the paperSubstantial claim- The authors state this as an assumption: The high pH buffer containing Mg2+ mimics the high effective pH and positively charged environment that can arise in lipid nanoparticles, protamine, and other formulations for mRNA therapeutics.
- Findingown data
Combining the dengue virus 5' and 3' UTRs in one mRNA results in an additive effect on ribosome loading.
“combining them in one mRNA resulted in an additive effect”
Quote in the paperSubstantial claim - Findingown data
Certain UTR combinations outperform hHBB in translation efficiency.
“certain UTR combinations outperform hHBB in translation efficiency”
Quote in the paperSubstantial claim - Findingown data
The ribosome load of CDS variants had no obvious correlation with CAI, GC content, MFE, addition of signal peptides, or nonsynonymous mutations.
“The ribosome load of CDS variants had no obvious correlation with the codon adaptation index (CAI), GC content, minimum free energy (MFE), addition of signal peptides, or nonsynonymous mutations (Table S1).”
Quote in the paperSubstantial claim - Findingreasoning
MEV-encoding CDS variants displayed less ribosome load than Nluc- or eGFP-encoding CDS variants, as expected from their shorter ORFs.
“The only clear effects on ribosome load were that MEV-encoding CDS variants displayed less ribosome load than Nluc- or eGFP-encoding CDS variants, as expected from their shorter ORFs.”
Quote in the paperNot a substantial claim - Findingown data
At 6 hours, Eterna- and Ribotree-derived designs tended to have similar or lower luciferase activities than the reference Nluc sequence.
“at 6 hours, both Eterna- and Ribotree-derived designs tended to have similar or lower luciferase activities than the reference Nluc sequence”
Quote in the paperSubstantial claim - Findingown data
In-solution half-lives correlated well with different metrics for predicted structure.
“and these values correlated well with different metrics for predicted structure (see below).”
Quote in the paperSubstantial claim- The authors state this as an assumption: The high pH buffer containing Mg2+ mimics the high effective pH and positively charged environment that can arise in lipid nanoparticles, protamine, and other formulations for mRNA therapeutics.
- Findingown data
DegScore correlated strongly with measured in-solution half-life (R = −0.55, p<0.001).
“DegScore correlated strongly with measured in-solution half-life (R = −0.55, p<0.001)”
Quote in the paperSubstantial claim - Findingown data
Predicted and measured luciferase activities showed a correlation of r = 0.71.
“The predicted and measured luciferase activities showed a correlation of r = 0.71 (Fig. 2F), supporting the accuracy of our model.”
Quote in the paperSubstantial claim- The authors state this as an assumption: Translation follows first-order kinetics and mRNA and protein decay are exponential.
- Findingown data
We obtained single-nucleotide-resolution measurements of 3030 RNA fragments using In-line-seq.
“In particular, we obtained single-nucleotide-resolution measurements of 3030 RNA fragments using In-line-seq, a version of a low-bias ligation and reverse transcription protocol (MAP-seq)64 adapted here for in-line hydrolysis profiles65 (Fig. 3B).”
Quote in the paperSubstantial claim0 of 2 sources checked- cites [64] Mikkola, S., Kaukinen, U. & Lönnberg, H. The effect of secondary structure on cleavage of the phosphodiester bonds of RNA. Cell Biochem. Biophys. 34, 95–119 (2001). source
- cites [65] Seetin, M. G., Kladwang, W., Bida, J. P. & Das, R. Massively parallel RNA chemical mapping with a reduced bias MAP-seq protocol. Methods Mol. Biol. 1086, 95–117 (2014). source
Checked before — its earlier verdict is held back until a new check runs.
- Findingown data
After 6 hours, two CDSs (LinearDesign-1 and GCrich_2) achieved similarly high protein levels compared to Nluc start, when combined with hHBB 5' and 3' UTRs.
“After 6 hours, two CDSs (LinearDesign-1 (Fig. 3) and GCrich_2) achieved similarly high protein levels compared to Nluc start, when combined with hHBB 5’ and 3’ UTRs.”
Quote in the paperSubstantial claim - Findingown data
Ribotree_LinearDesign_degscoreall_1 mRNA exhibited a 1.7-fold increase in protein expression relative to Nluc start.
“and exhibited high levels of protein expression in cells (1.7-fold increase, relative to Nluc start) (Ribotree_LinearDesign_degscoreall_1; Fig. 4C).”
Quote in the paperSubstantial claim - Findingown data
A key determinant of in-solution RNA degradation is the presence of uridine.
“a key determinant of in-solution RNA degradation is the presence of uridine”
Quote in the paperSubstantial claim - Findingown data
Among the three UTR combinations and six CDS designs tested, most demonstrated lower overall luciferase activity than the reference start Nluc with hHBB UTRs.
“Among the three UTR combinations and six CDS designs tested, most demonstrated lower overall luciferase activity than the reference start Nluc with hHBB UTRs (Fig 4A).”
Quote in the paperNot a substantial claim - Findingown data
A closer look revealed additional sequence and structure dependent rules for in-line hydrolysis.
“but a closer look revealed additional sequence and structure dependent rules for in-line hydrolysis.”
Quote in the paperSubstantial claim - Findingown data
The dengue virus 5' UTR individually increases ribosome loading.
“the dengue virus 5’ and 3’ UTRs, which both individually increase ribosome loading”
Quote in the paperSubstantial claim - Findingreasoning
In-cell mRNA stability may be a greater driver of protein output than high ribosome load, particularly when proteins need to be expressed from a single dose of mRNAs for long periods of time.
“we find that in-cell mRNA stability may be a greater driver of protein output than high ribosome load particularly when proteins need to be expressed from a single dose of mRNAs for long periods of time.”
Quote in the paperSubstantial claim - Findingreasoning
Combining optimal UTRs, DegScore optimization with RiboTree, and ψ modification achieves high mRNA stability.
“By combining optimal UTRs, DegScore optimization with RiboTree, and ψ modification, we are able to achieve high mRNA stability”
Quote in the paperSubstantial claim - Interpretationown data
There is a tradeoff between ribosome load and mRNA stability.
“this observation foreshadowed a tradeoff between ribosome load and mRNA stability that we dissect in greater detail below.”
- Also stated in: § In-cell mRNA stability is a major predictor of total protein output · plain
“Importantly, these findings identify an unexpected rule for the design of mRNA – excessively increasing translation efficiency may negatively impact mRNA stability.”
Quote in the paperSubstantial claim - Also stated in: § In-cell mRNA stability is a major predictor of total protein output · plain
- Study design and conductown data
PERSIST-seq enables systematic determination of the effects of UTR, codon choice and RNA structure on mRNA translation rates in human cells and on mRNA stability in cells and in solution.
“We present a massively parallel reporter assay termed Pooled Evaluation of mRNA in-solution Stability, and In-cell Stability and Translation RNA-seq (PERSIST-seq), which enables systematic determination of the effects of UTR, codon choice and RNA structure on mRNA translation rates in human cells and on mRNA stability, both in cells and in solution.”
Quote in the paperSubstantial claim - Interpretationown data
In-cell mRNA stability is a greater driver of total protein output than high ribosome load.
“We find that, surprisingly, in-cell stability is a greater driver of protein output than high ribosome load.”
- Also stated in: § In-cell mRNA stability is a major predictor of total protein output · boosted
“Taken together, our large-scale and unbiased pooled measurement of translation and mRNA stability provides a simple but powerful platform to test large numbers of different mRNA sequence designs for desired protein expression and has allowed us to importantly infer that in-cell mRNA stability is the dominant predictor of total protein output (Fig. 2C,E).”
Quote in the paperSubstantial claim- The authors state this as an assumption: Translation follows first-order kinetics and mRNA and protein decay are exponential.
- Also stated in: § In-cell mRNA stability is a major predictor of total protein output · boosted
- Interpretationown data
Different 5' UTRs have strong potential to tune translational efficiency of target mRNAs, more than 3' UTR or CDS regions.
“These data suggested strong potential for using different 5’ UTRs to tune translational efficiency of target mRNAs – more than for any other region (3’ UTR or CDS).”
Quote in the paperSubstantial claim - Interpretationnone given
This study represents the first large-scale screen of mRNA redesigned across its entire length.
“This represents the first large-scale screen of mRNA redesigned across its entire length.”
Quote in the paperNot a substantial claim - Interpretationreasoning
The combination of optimized UTRs for expression, DegScore-optimized CDS structure, and ψ modification provides a general technology that can be applied to stabilize and increase protein expression of candidate mRNA therapeutics.
“Together, the combination of optimized UTRs for expression, DegScore-optimized CDS structure, and ψ modification provides a general technology that can be applied to stabilize and increase protein expression of candidate mRNA therapeutics.”
Quote in the paperSubstantial claim - Interpretationreasoning
The model enables identification of optimal mRNA designs without the need to individually test all mRNAs for protein output.
“This model enables identification of optimal mRNA designs without the need to individually test all mRNAs for protein output.”
Quote in the paperSubstantial claim- The authors state this as an assumption: Translation follows first-order kinetics and mRNA and protein decay are exponential.
- Interpretationown data
In-cell mRNA stability is a primary driver of protein output.
“This finding is consistent with faster mRNA decay compared to hHBB UTRs and our results supporting that in-cell mRNA stability is a primary driver of protein output (Fig. 2C, E).”
- Also stated in: § One-by-one tests confirm additivity of UTR, CDS, and ψ improvements · boosted
“Overall, these results demonstrated the importance of mRNA stability to protein output”
Quote in the paperSubstantial claim - Also stated in: § One-by-one tests confirm additivity of UTR, CDS, and ψ improvements · boosted
- Interpretationreasoning
For short expression (early time points after mRNA transfection) or for "above-threshold" protein half-lives, translation can become the dominant predictor.
“However, for short expression (early time points after mRNA transfection) or for “above-threshold” protein half-lives, translation can become the dominant predictor.”
Quote in the paperSubstantial claim- The authors state this as an assumption: Translation follows first-order kinetics and mRNA and protein decay are exponential.
- Interpretationown data
Downstream luciferase expression can be further amplified by ψ modification of mRNAs.
“Moreover, downstream luciferase expression can be further amplified by ψ modification of mRNAs.”
Quote in the paperSubstantial claim - Interpretationown data
Combining UTRs that facilitate high levels of translation with structural optimization of CDSs via LinearDesign and DegScore-guided RiboTree design can enhance both in-solution stability and total in-cell protein output of mRNAs.
“Taken together, our detailed studies on individual mRNAs (Fig. 4) indicate that combining UTRs that facilitate high levels of translation alongside structural optimization of CDSs via LinearDesign and DegScore-guided RiboTree design, we can enhance both in-solution stability and total in-cell protein output of mRNAs.”
Quote in the paperSubstantial claim - Interpretationreasoning
Longer or more branched double-stranded RNA stems may potentially hinder the ability of the ribosome to unwind RNA secondary structure.
“For instance, longer or more branched double-stranded RNA stems may potentially hinder the ability of the ribosome to unwind RNA secondary structure.”
Quote in the paperSubstantial claim - Interpretationown data
In-solution RNA stability can be significantly further improved by incorporating modified U nucleosides, beyond redesigning RNA sequences to take on stable structure.
“This finding indicated that beyond redesigning RNA sequences to take on stable structure, in-solution RNA stability can be significantly further improved by incorporating modified U nucleosides.”
Quote in the paperSubstantial claim - Interpretationreasoning
There does not have to be a tradeoff between mRNA structure, stability, and protein output.
“There does not have to be a tradeoff between mRNA structure, stability, and protein output.”
Quote in the paperSubstantial claim - Interpretationown data
The model's accuracy is supported by the correlation between predicted and measured luciferase activities.
“The predicted and measured luciferase activities showed a correlation of r = 0.71 (Fig. 2F), supporting the accuracy of our model.”
Quote in the paperSubstantial claim- The authors state this as an assumption: Translation follows first-order kinetics and mRNA and protein decay are exponential.
- Interpretationown data
Predicted protein expression per mole of transfected mRNA is modeled to be mostly driven by the in-cell mRNA half-life.
“Overall, predicted protein expression per mole of transfected mRNA is modeled to be mostly driven by the in-cell mRNA half-life (Fig. 2C, top panel), which more closely trends with predicted protein expression (Fig. 2E) than ribosome load does (Fig. 2C, lower panel).”
Quote in the paperSubstantial claim- The authors state this as an assumption: Translation follows first-order kinetics and mRNA and protein decay are exponential.
- Interpretationreasoning
Increased polysome load appears counterproductive to maximizing the total amount of protein expressed over time.
“Stated differently, increased polysome load appears counterproductive to the goal of maximizing the total amount of protein expressed over time.”
Quote in the paperSubstantial claim - Interpretationown data
DegScore enables in silico optimization of any RNA sequence.
“which enables in silico optimization of any RNA sequence”
Quote in the paperSubstantial claim - Study design and conductown data
DegScore, a model for hydrolytic degradation, was independently validated on PERSIST-seq data.
“DegScore, a model for hydrolytic degradation that was independently validated on PERSIST-seq data”
Quote in the paperSubstantial claim - Study design and conductreasoning
The study focused on characterizing degradation of naked, non-formulated mRNAs.
“our study has focused on characterizing degradation of naked, non-formulated mRNAs”
Quote in the paperSubstantial claim - Interpretationown data
A new mRNA design methodology can dramatically enhance mRNA stability in aqueous solution.
“we report a new mRNA design methodology that can dramatically enhance mRNA stability in aqueous solution”
Quote in the paperSubstantial claim - Interpretationown data
A new mRNA design methodology can sustain or even increase protein expression inside cells.
“we report a new mRNA design methodology that can dramatically enhance mRNA stability in aqueous solution while sustaining or even increasing protein expression inside cells”
Quote in the paperSubstantial claim - Interpretationreasoning
Depending on the desired parameters (early burst of high protein expression or total protein output integrated over a longer time), the most optimal set of UTRs can vary.
“Therefore, depending on the desired parameters (early burst of high protein expression or total protein output integrated over a longer time), the most optimal set of UTRs can vary.”
Quote in the paperSubstantial claim- The authors state this as an assumption: Translation follows first-order kinetics and mRNA and protein decay are exponential.
- Interpretationown data
Enhanced in-cell half-life of a structured mRNA can compensate for low translation efficiency.
“The result was nevertheless consistent with our model that enhanced in-cell half-life of a structured mRNA can compensate for low translation efficiency (Fig. 2C–E).”
Quote in the paperSubstantial claim - Interpretationown data
The global assessment of in-solution RNA degradation using PERSIST-Seq reveals pronounced effects of RNA length and structure on RNA half-life in solution.
“Overall, the global assessment of in-solution RNA degradation using PERSIST-Seq reveals pronounced effects of RNA length and structure on RNA half-life in solution.”
Quote in the paperSubstantial claim- The authors state this as an assumption: The high pH buffer containing Mg2+ mimics the high effective pH and positively charged environment that can arise in lipid nanoparticles, protamine, and other formulations for mRNA therapeutics.
- Interpretationreasoning
These modifications are consistent with mitigating hydrolysis as modeled in the DegScore predictor.
“These modifications are consistent with mitigating hydrolysis as modeled in the DegScore predictor (Fig. 3D).”
Quote in the paperSubstantial claim - Study design and conductown data
Measurements without Mg2+, at lower pH, and higher temperature gave strongly correlated results to the accelerated degradation conditions used for PERSIST-seq in-solution stability measurements.
“We matched the accelerated degradation conditions used for PERSIST-seq in-solution stability measurements, but also verified that measurements without Mg2+, at lower pH, and higher temperature gave strongly correlated results (Fig. S4A).”
Quote in the paperNot a substantial claim - Interpretationown data
Excessively increasing translation efficiency may negatively impact mRNA stability.
“Importantly, these findings identify an unexpected rule for the design of mRNA – excessively increasing translation efficiency may negatively impact mRNA stability.”
Quote in the paperSubstantial claim - Interpretationown data
Despite ψ modification and highly structured CDSs, translation is sustained.
“indicating that, despite ψ modification and highly structured CDSs, translation is sustained.”
Quote in the paperSubstantial claim - Interpretationown data
The simultaneous increase in in-solution stability and in-cell protein expression for Ribotree_LinearDesign_degscoreall_1 demonstrates the impact of the design rules for mRNA.
“This simultaneous increase in in-solution stability with improved and sustained in-cell protein expression provided a strong demonstration of the impact of our design rules for mRNA.”
Quote in the paperSubstantial claim - Interpretationreasoning
Reducing the overall presence of Us in loops and reducing the number of hairpins to generate a 'linear' highly double-stranded mRNA can lead to enhanced mRNA stability and protein expression.
“Taken together, these data suggest that by reducing the overall presence of Us in loops and reducing the number of hairpins to generate a “linear” highly double-stranded mRNA can lead to enhanced mRNA stability and protein expression.”
Quote in the paperSubstantial claim - Interpretationreasoning
The suppression of in-line hydrolysis by ψ/m1ψ appears to be due to local chemical or structural effects.
“the suppression of in-line hydrolysis appears to be due to local chemical or structural effects.”
Quote in the paperSubstantial claim
- May combine two claims. 22
- Classified as probably not a substantial claim. 15
- The quote only partly states this claim. 1
May combine two claims.
PremisecitationmRNA vaccines still suffer from decreased efficacy due to poor RNA stability in solution and in vivo and to limited expression of the payload mRNA.
“mRNA vaccines still suffer from decreased efficacy due to poor RNA stability in solution and in vivo and to limited expression of the payload mRNA; these are all pivotal issues that need to be carefully optimized for preclinical and clinical applications3–6.”
Quote in the paperSubstantial claim3 of 4 sources checked- cites [3] Sahin, U., Karikó, K. & Türeci, Ö. mRNA-based therapeutics-developing a new class of drugs. Nat. Rev. Drug Discov. 13, 759–780 (2014). source
The sections on improving mRNA delivery and on translation and stability describe extracellular degradation, intracellular stability, and achieving sufficient expression of the encoded protein as challenges. But Box 4 says RNA is stable in RNase-free environments, while the Conclusions say mRNA instability has been efficiently addressed. The paper therefore does not support a blanket claim that poor stability in solution and in vivo still reduces vaccine efficacy. (LLM, conf=0.88)
Experimental — accuracy not yet measured - cites [4] Jackson, N. A. C., Kester, K. E., Casimiro, D., Gurunathan, S. & DeRosa, F. The promise of mRNA vaccines: a biotech and industrial perspective. npj Vaccines 5, 11 (2020). source
The “State-of-the-art” section says mRNA is susceptible to degradation during delivery and that construct quality affects expression. “Perspective #1” links improved stability and expression to greater antigen production and potential potency. The cited paper does not specifically establish poor stability in solution as a cause of decreased vaccine efficacy. (LLM, conf=0.84)
Experimental — accuracy not yet measured - cites [5] Weng, Y. et al. The challenge and prospect of mRNA therapeutics landscape. Biotechnol. Adv. 40, 107534 (2020). source
- cites [6] Crommelin, D. J. A., Anchordoquy, T. J., Volkin, D. B., Jiskoot, W. & Mastrobattista, E. Addressing the cold reality of mRNA vaccine stability. J. Pharm. Sci. 110, 997–1001 (2021). source
The Historical Perspective section (page unavailable) says mRNA degradation can reduce vaccine potency by slowing translation and limiting antigen expression; it also discusses degradation in solution. The Concluding Considerations section (page unavailable) links in vivo delivery and antigen production to immunogenicity, but our copy does not establish poor RNA stability in vivo as a cause of decreased vaccine efficacy. (LLM, conf=0.82)
Experimental — accuracy not yet measured
May combine two claims.
PremisecitationRNA is inherently unstable due to its 2'-hydroxyl group, and degradation of the mRNA in solution by in-line nucleophilic attack, potentially aggravated by formulations, poses a major challenge.
“In particular, RNA is inherently unstable due its 2’-hydroxyl group, and degradation of the mRNA in solution by in-line nucleophilic attack, potentially aggravated by formulations, poses a major challenge6.”
Quote in the paperSubstantial claim1 of 1 sources checked- cites [6] Crommelin, D. J. A., Anchordoquy, T. J., Volkin, D. B., Jiskoot, W. & Mastrobattista, E. Addressing the cold reality of mRNA vaccine stability. J. Pharm. Sci. 110, 997–1001 (2021). source
The Historical Perspective section (page not provided) describes mRNA degradation in solution, including phosphodiester-bond hydrolysis, and says cationic lipid formulations may increase cleavage rates. The Concluding Considerations section treats stability as a major formulation challenge. Our copy does not identify the 2′-hydroxyl group or in-line nucleophilic attack as the mechanism, so those specific parts are not supported. (LLM, conf=0.86)
Experimental — accuracy not yet measured
May combine two claims.
Premisecitationψ and m1ψ substitutions for U have been widely adopted for mRNA therapeutics and vaccines due to improved in-cell translation and better control of innate immune responses.
“In particular, we focused on ψ and m1ψ, since these substitutions for U have been widely adopted for mRNA therapeutics and vaccines due to improved in-cell translation and to better control of innate immune responses2,3,8,67 through avoidance of recognition by cellular toll-like receptors (TLR7 and TLR8)68, RIG‑I, and PKR69–71.”
Quote in the paperSubstantial claim6 of 8 sources checked- cites [2] Pardi, N., Hogan, M. J., Porter, F. W. & Weissman, D. mRNA vaccines - a new era in vaccinology. Nat. Rev. Drug Discov. 17, 261–279 (2018). source
The 'Modulation of immunogenicity' section (page unavailable) says pseudouridine and 1-methylpseudouridine reduce innate immune sensing and that nucleoside-modified mRNA improves translation. It links these advances to interest in vaccines and protein-replacement therapies, but does not establish that both substitutions were widely adopted for those uses; the vaccine section describes the platform as novel. (LLM, conf=0.86)
Experimental — accuracy not yet measured - cites [3] Sahin, U., Karikó, K. & Türeci, Ö. mRNA-based therapeutics-developing a new class of drugs. Nat. Rev. Drug Discov. 13, 759–780 (2014). source
Box 1 reports that pseudouridine-modified mRNA can improve translation and reduce innate immune activation, including activation of TLR7 and TLR8. It does not identify m1ψ or establish that both substitutions were widely adopted for mRNA therapeutics and vaccines. No page number is available in our copy. (LLM, conf=0.87)
Experimental — accuracy not yet measured - cites [8] Mauger, D. M. et al. mRNA structure regulates protein expression through changes in functional half-life. Proc. Natl Acad. Sci. USA 116, 24075–24083 (2019). source
The Methods (mRNA Preparation) identify Ψ and m1Ψ as substitutions for U. The Results (RNA Sequence and Nucleotide Modifications Combine to Determine Protein Expression) report increased cell expression with m1Ψ and describe m1Ψ as having reduced immunogenicity. They do not establish improved translation for Ψ or widespread adoption of both substitutions in therapeutics and vaccines. The TLR, RIG-I, and PKR mechanism is attached to other citations in the citing sentence. (LLM, conf=0.85)
Experimental — accuracy not yet measured - cites [67] Lorenz, R. et al. ViennaRNA Package 2.0. Algorithms Mol. Biol. 6, 26 (2011). source
The Background section discusses computational RNA folding and RNA–RNA interactions, not the use of ψ or m1ψ in mRNA therapeutics or vaccines. Searches for those substitutions, in-cell translation, and innate immune receptors found no passage addressing the attributed claim. (LLM, conf=0.76)
Experimental — accuracy not yet measured - cites [68] Diedenhofen, B. & Musch, J. cocor: a comprehensive solution for the statistical comparison of correlations. PLoS ONE 10, e0121945 (2015). source
The Introduction and Code Examples discuss statistical tests for comparing correlations, not mRNA therapeutics or vaccines. The supplied passages do not address ψ or m1ψ substitutions, translation, or innate immune responses, so our copy provides no evidence for the attributed claim. (LLM, conf=0.78)
Experimental — accuracy not yet measured - cites [69] Karikó, K. et al. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol. Ther. 16, 1833–1840 (2008). source
The Results section reports that Ψ-containing mRNA translated more efficiently than unmodified mRNA in cultured cells, and the Discussion reports diminished immunogenicity in vivo and potential therapeutic and vaccine uses. The paper does not establish that Ψ or m1ψ had been widely adopted, and it does not report results for m1ψ. No page numbers are available in our copy. (LLM, conf=0.88)
Experimental — accuracy not yet measured - cites [70] Karikó, K., Buckstein, M., Ni, H. & Weissman, D. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 23, 165–175 (2005). source
- cites [71] Hornung, V. et al. 5′-Triphosphate RNA is the ligand for RIG-I. Science 314, 994–997 (2006). source
May combine two claims.
Findingown dataNucleotide-resolution data on thousands of small, structured model RNAs from the Eterna platform revealed novel design rules for reducing solution hydrolysis and enabled development of DegScore, a regression model for in silico RNA sequence optimization for enhanced in-solution stability.
“Nucleotide-resolution data on thousands of small, structured model RNAs from the Eterna platform revealed novel design rules for reducing solution hydrolysis and enabled development of a regression model termed DegScore that enables in silico RNA sequence optimization for enhanced in-solution stability.”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataDeleting the full 5' half (dSL1-3) or the 3' half (dSL4-5) of the SARS-CoV-2 5' UTR overall increased ribosome load.
“Deleting the full 5’ half (dSL1–3) or the 3’ half (dSL4–5) of the 5’ UTR overall increased ribosome load.”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataThe k-mer effects included significant depletion of 5' UTRs containing out-of-frame AUG start codons relative to the main ORF and enrichments of short stem-loop motifs promoting translation.
“These effects included significant depletion of 5’ UTRs that contain out-of-frame AUG start codons relative to the main ORF and enrichments of short stem-loop motifs promoting translation (Fig. S2F).”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataThe dengue virus 5' and 3' UTRs both individually increase ribosome loading, and combining them into one mRNA resulted in an additive effect.
“The dengue virus 5’ and 3’ UTRs both individually increase ribosome loading, and combining them into one mRNA resulted in an additive effect (Fig. 1E, Table S1).”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataThe ratio of these half-lives, 3.0±0.7, matched within error the inverse ratio of the lengths of the mRNA regions captured by RT-PCR (958 nt/250 nt = 3.8), supporting theoretical predictions of length effects.
“Indeed, the ratio of these half-lives, 3.0±0.7, matched within error the inverse ratio of the lengths of the mRNA regions captured by RT-PCR (958 nt/250 nt = 3.8), supporting theoretical predictions of length effects.”
Quote in the paperSubstantial claim- The authors state this as an assumption: The high pH buffer containing Mg2+ mimics the high effective pH and positively charged environment that can arise in lipid nanoparticles, protamine, and other formulations for mRNA therapeutics.
May combine two claims.
Findingown dataOverall, a wide range of UTR-dependent translation efficiencies was observed in PERSIST-seq, which could be further fine-tuned with specific UTR sequence or CDS structure alterations.
“Overall, we observed a wide range of UTR-dependent translation efficiencies in PERSIST-seq which could be further fine-tuned with specific UTR sequence or CDS structure alterations.”
Quote in the paperSubstantial claimMay combine two claims.
Findingown dataFor Nluc-encoding mRNAs, CDS variants were similar in ribosome load or showed a shift towards being less loaded with ribosomes.
“For Nluc-encoding mRNAs, CDS variants were similar in ribosome load or showed a shift towards being less loaded with ribosomes.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
Findingown dataThe two distinct normalization approaches gave the same results within estimated error.
“These distinct approaches to normalizing the data gave the same results within estimated error (see below).”
Quote in the paperNot a substantial claim- The authors state this as an assumption: The majority of the other RNA in the lane were degradation products from the mRNA of interest.
May combine two claims.
Findingown dataOf the DegScore coefficients, G and C were most favorable (least hydrolysis) to have 3' of the linkage, followed by A, and 3' U was most detrimental to degradation.
“Of these coefficients, G and C were the most favorable (least hydrolysis) to have 3’ of the linkage, followed by A, and a 3’ U was most detrimental to degradation, matching our prior observations.”
Quote in the paperSubstantial claimMay combine two claims.
Interpretationown dataThe study demonstrates simultaneous improvement of mRNA stability and protein expression and provides a computational-experimental platform for the enhancement of mRNA medicines.
“Together, our study demonstrates simultaneous improvement of mRNA stability and protein expression and provides a computational-experimental platform for the enhancement of mRNA medicines.”
Quote in the paperSubstantial claimMay combine two claims.
Interpretationown data"Superfolder" mRNAs can be designed to improve both stability and expression, and this improvement is further enhanced through pseudouridine nucleoside modification.
“Our findings show that “superfolder” mRNAs can be designed to improve both stability and expression that are further enhanced through pseudouridine nucleoside modification.”
Quote in the paperSubstantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
Study design and conductown dataNormalization of the mRNA stability data was performed using two different methods used to cross-validate.
“Normalization was performed using two different methods used to cross-validate.”
Quote in the paperNot a substantial claim- The authors state this as an assumption: The majority of the other RNA in the lane were degradation products from the mRNA of interest.
May combine two claims.
Interpretationown dataThis is the first massively parallel methodology and large-scale data set applying in-line probing to RNA.
“This is the first massively parallel methodology and large-scale data set applying in-line probing to RNA.”
Quote in the paperSubstantial claimClassified as probably not a substantial claim.
Study design and conductreasoningSignal peptide sequences were removed from the CDS for templates and mRNA used in transfection and luciferase activity experiments because the assay relies on accumulation of luciferase in the cytosol.
“Because this assay relies on accumulation of luciferase in the cytosol, any signal peptides sequences (Table S1) were removed from the CDS for templates and mRNA for these transfection and luciferase activity experiments.”
Quote in the paperSubstantial claim- Rests on an assumption: The luciferase assay relies on accumulation of luciferase in the cytosol.
Classified as probably not a substantial claim.
Study design and conductnone givenThe count matrix was log transformed and normalized column-wise using a linear fit on the dilution series of spike-in constructs in each sample.
“The count matrix was log transformed and normalized column-wise using a linear fit on the dilution series of spike-in constructs in each sample.”
Quote in the paperSubstantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
Study design and conductnone givenBlinding and randomization were not used in any of the experiments.
“Blinding and randomization were not used in any of the experiments.”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
Study design and conductown dataAmplification of the full-length cDNA product was verified on an agarose gel stained with SYBRSafe.
“Amplification of the full-length cDNA product was verified on an agarose gel stained with SYBRSafe (Invitrogen).”
Quote in the paperNot a substantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
Study design and conductnone givenIn all cases, multiple independent experiments were performed on different days to verify the reproducibility of experimental findings.
“In all cases, multiple independent experiments were performed on different days to verify the reproducibility of experimental findings.”
Quote in the paperNot a substantial claimClassified as probably not a substantial claim. May combine two claims.
Study design and conductown dataSequences were filtered for low experimental noise and to ensure that the structure predicted in ViennaRNA matched the structure inferred through SHAPE mapping data collected at the same time; these filters resulted in 2165 sequences and corresponding secondary structures.
“For analysis of sequence and structure motifs, sequences were filtered for low experimental noise and to ensure that the structure predicted in ViennaRNA66 matched the structure inferred through SHAPE mapping data collected at the same time (see Methods); these filters resulted in 2165 sequences and corresponding secondary structures.”
Quote in the paperSubstantial claim0 of 1 sources checked- cites [66] Regulski, E. E. & Breaker, R. R. In-line probing analysis of riboswitches. Methods Mol. Biol. 419, 53–67 (2008). source
May combine two claims.
InterpretationreasoningOur study presents advances in tackling both RNA instability and the need for mRNA to compete for translation machinery, building on two new high-throughput technologies.
“Our study presents advances in tackling both of these challenges, building on two new high-throughput technologies.”
Quote in the paperSubstantial claim- Rests on an assumption: Once delivered into patient cells, the candidate mRNA must outcompete other cytoplasmic mRNAs for the translation machinery and avoid the cellular mRNA degradation machinery to express maximum amounts of the desired encoded protein.
May combine two claims.
Interpretationown dataStructured CDS regions and a wide variety of 5' UTR elements from cellular and viral origins can sustain or even improve in-cell translation efficiency compared to reference mRNA sequences.
“Taken together with our results above, these PERSIST-seq measurements indicate that structured CDS regions and a wide variety of 5’ UTR elements from cellular and viral origins can sustain or even improve in-cell translation efficiency compared to reference mRNA sequences.”
Quote in the paperSubstantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
InterpretationreasoningFor applications with very short mRNAs or much longer mRNAs, the best UTRs and the sweet spot for optimal translation efficiency may be different from those identified in this study.
“for applications with very short mRNAs (as are in use for multi-epitope cancer vaccines, and represented in our MEV sequences80) or much longer mRNAs (as are needed for antigens like the SARS-CoV-2 Spike protein), the best UTRs and the sweet spot for optimal translation efficiency may be different.”
Quote in the paperNot a substantial claimMay combine two claims.
InterpretationreasoningSynthesis of mRNAs with modifications is a simple method to achieve significantly greater in-solution stability while sustaining protein expression.
“Synthesis of mRNAs with modifications – already in wide use for mitigating innate immune response and translational shutdown by mRNA therapeutics67,68,74,75 – is therefore a simple method to achieve significantly greater in-solution stability while sustaining protein expression.”
Quote in the paperSubstantial claimMay combine two claims.
Study design and conductreasoningDegScore was trained on degradation from unmodified nucleotides and does not account for the observed stabilization via ψ.
“DegScore was trained on degradation from unmodified nucleotides that does not account for our observed stabilization via ψ”
Quote in the paperSubstantial claimClassified as probably not a substantial claim.
Study design and conductnone givenThe experiments were limited to HEK293T as model human cells.
“our experiments were limited to HEK293T as model human cells”
Quote in the paperSubstantial claimMay combine two claims.
InterpretationreasoningThe best UTRs for high protein output are likely to be cell-type dependent and will vary from application to application.
“the best UTRs for high protein output are likely to be cell-type dependent and therefore will vary from application to application”
Quote in the paperSubstantial claimMay combine two claims.
Interpretationown dataThese results validate and demonstrate a modular and flexible platform that is applicable to potentially any protein target of choice and can accelerate the design of overall improved mRNA therapeutics solutions.
“These results validate and demonstrate a modular and flexible platform that is applicable to potentially any protein target of choice and can accelerate the design of overall improved mRNA therapeutics solutions.”
Quote in the paperSubstantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
Study design and conductnone givenAfter purification, RNA was checked again by PAGE-Urea-TBE gel and visualized by SYBR Gold.
“Subsequently, RNA was purified using Ampure beads + 40% polyethylene glycol 8000 (7:3) and checked again by PAGE-Urea-TBE gel and visualized by SYBR Gold.”
Quote in the paperNot a substantial claimClassified as probably not a substantial claim.
Study design and conductnone givenThe integrity of each sample was checked by loading total RNA alongside a spike-in control onto a PAGE-Urea-TBE gel and visualized by SYBR Gold.
“The integrity of each sample was checked by loading 5 μL of total RNA alongside a spike-in control (P4P62HP, 50 ng) onto a PAGE-Urea-TBE gel and visualized by SYBR Gold (Thermo Fisher).”
Quote in the paperSubstantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
Premisecitationψ and derivatives have been reported to stabilize mRNAs against decay in cells.
“While ψ and derivatives have been reported to stabilize mRNAs against decay in cells67, the effects of these modifications on mRNA stability in solution have not been reported.”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [67] Lorenz, R. et al. ViennaRNA Package 2.0. Algorithms Mol. Biol. 6, 26 (2011). source
Not checked in the free run.
Classified as probably not a substantial claim. The quote only partly states this claim.
Study design and conductnone givenEach experiment was performed a minimum of three independent times.
“Each experiment was performed a minimum of three independent times.”
Quote in the paperSubstantial claimProbably not a substantial claim: may not pass S3 (load-bearing).
PremisecitationNon-formulated mRNAs appear optimal for certain applications including personalized cancer mRNA vaccines.
“such non-formulated mRNAs also appear optimal for certain applications including personalized cancer mRNA vaccines81”
Quote in the paperNot a substantial claim0 of 1 sources checked- cites [81] Hu, B., Guo, H., Zhou, P. & Shi, Z.-L. Characteristics of SARS-CoV-2 and COVID-19. Nat. Rev. Microbiol. 19, 141–154 (2020). source
Checked before — its earlier verdict is held back until a new check runs.
May combine two claims.
Interpretationown dataResistance to RNA hydrolysis, as predicted by DegScore and quantified by in-solution half-life, is important for longer protein expression, but other RNA sequence and structural features govern protein expression at shorter timescales.
“These observations suggest that resistance to RNA hydrolysis, as predicted by DegScore and quantified by in-solution half-life, is important for longer protein expression, but that other RNA sequence and structural features govern protein expression at shorter timescales.”
Quote in the paperSubstantial claim
The authors state this as an assumption.
Nucleotides that are not base paired in structure are uniformly prone to hydrolytic degradation.
“the assumption that nucleotides that are not base paired in structure would be uniformly prone to hydrolytic degradation7.”
The authors state this as an assumption.
Translation follows first-order kinetics and mRNA and protein decay are exponential.
“assuming first-order rate of translation and exponential decay for mRNAs and for proteins.”
The authors state this as an assumption.
The high pH buffer containing Mg2+ mimics the high effective pH and positively charged environment that can arise in lipid nanoparticles, protamine, and other formulations for mRNA therapeutics.
“To mimic the high effective pH and positively charged environment that can arise in lipid nanoparticles, protamine, and other formulations for mRNA therapeutics6, we used a high pH buffer containing Mg2+ to accelerate degradation (10 mM MgCl2, 50 mM Na-CHES, pH 10.0, 24 °C); conditions without Mg2+ or at lower pH lead to similar conclusions on relative stabilities across RNA variants (see below).”
The paper relies on this without support.
The effects of ψ modifications on mRNA stability in solution have not been reported.
“While ψ and derivatives have been reported to stabilize mRNAs against decay in cells67, the effects of these modifications on mRNA stability in solution have not been reported.”
The paper relies on this without support.
High mRNA structure adversely impacts the cellular translational apparatus.
“the expectation that high mRNA structure should adversely impact the cellular translational apparatus.”
The paper relies on this without support.
Once delivered into patient cells, the candidate mRNA must outcompete other cytoplasmic mRNAs for the translation machinery and avoid the cellular mRNA degradation machinery to express maximum amounts of the desired encoded protein.
“Moreover, once delivered into patient cells, the candidate mRNA must outcompete other cytoplasmic mRNAs for the translation machinery and avoid the cellular mRNA degradation machinery to express maximum amounts of the desired encoded protein.”
The authors state this as an assumption.
mRNA translation and mRNA/protein decay follow first-order kinetics.
“To calculated the expected protein levels assuming first order kinetics of mRNA translation and mRNA/protein decay, the following differential equations are used:”
The paper relies on this without support.
The luciferase assay relies on accumulation of luciferase in the cytosol.
“Because this assay relies on accumulation of luciferase in the cytosol, any signal peptides sequences (Table S1) were removed from the CDS for templates and mRNA for these transfection and luciferase activity experiments.”
The authors state this as an assumption.
The majority of the other RNA in the lane were degradation products from the mRNA of interest.
“assuming that the majority of the other RNA in the lane were degradation products from the mRNA of interest”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In a recent study, LinearDesign-generated sequences with three different UTRs exhibited stronger in vitro protein expression over all benchmark sequences.
“which is also consistent with a recent study29 in which LinearDesign-generated sequences with three different UTRs exhibited stronger in vitro protein expression over all benchmark sequences”
From Algorithm for optimized mRNA design improves stability and immunogenicity (2023) · cites this paper as [29]
The Results section, “One-by-one tests confirm additivity of UTR, CDS, and ψ improvements” (page unavailable), reports testing a LinearDesign-1 sequence with three UTR combinations and finding twice the luciferase yield of the Nluc reference at 24 hours with hHBB UTRs. It does not support superiority across all three UTR combinations or over all benchmark sequences: expression with another UTR combination fell by 24 hours, and most of the tested combinations had lower overall activity than the reference. (LLM, conf=0.87)
Experimental — accuracy not yet measuredLinearDesign is likely to remain effective independent of the choice of UTRs.
“This evidence suggests that LinearDesign is likely to remain effective independent of the choice of UTRs, which is also consistent with a recent study29 in which LinearDesign-generated sequences with three different UTRs exhibited stronger in vitro protein expression over all benchmark sequences”
From Algorithm for optimized mRNA design improves stability and immunogenicity (2023) · cites this paper as [29]
The Results section, “One-by-one tests confirm additivity of UTR, CDS, and ψ improvements” (page unavailable), tests LinearDesign-1 with three UTR combinations and reports twice the 24-hour luciferase yield of the Nluc reference when paired with hHBB UTRs. It does not establish effectiveness independent of UTR choice or stronger expression than all benchmarks across all three combinations; the section says most tested combinations had lower overall activity than the reference. The Discussion (page unavailable) also notes that optimal UTRs may vary by application and cell type. (LLM, conf=0.88)
Experimental — accuracy not yet measuredLinearDesign had a central role in their work as the starting point of their optimizations.
“LinearDesign had a central role in their work as the starting point of their optimizations (see figure 4b of their paper), followed by fine-tunings by both human players and a Monte Carlo tree search algorithm.”
From Algorithm for optimized mRNA design improves stability and immunogenicity (2023) · cites this paper as [29]
The Results section (Fig. 4C; page not specified) says that both Eterna participants and RiboTree modified designs from the LinearDesign server. But the Results section (Fig. 4B; page not specified) also describes other design approaches and says RiboTree could start from random sequences, so LinearDesign was not the starting point for all the paper’s optimizations. (LLM, conf=0.85)
Experimental — accuracy not yet measuredLinearDesign-generated sequences showed strong stability and protein expression results with different UTRs, independently confirming our in vitro experiments.
“LinearDesign-generated sequences showed strong stability and protein expression results with different UTRs (figures 2g and 4a of their paper), independently confirming our in vitro experiments.”
From Algorithm for optimized mRNA design improves stability and immunogenicity (2023) · cites this paper as [29]
The Results section reports a long in-solution half-life for LinearDesign-1 and high protein output with hHBB UTRs (Fig. 4A). It also tested different UTR combinations, but most produced lower protein output; one alternative approached hHBB expression at 6 hours but fell behind by 24 hours. Thus, strong performance across different UTRs overstates the findings. The statement about confirming the citing authors’ experiments is their own interpretation. (LLM, conf=0.85)
Experimental — accuracy not yet measuredThey did not perform any in vivo validations.
“However, they did not perform any in vivo validations.”
From Algorithm for optimized mRNA design improves stability and immunogenicity (2023) · cites this paper as [29]
Another recent work optimized mRNA designs and screened them via an experimental platform.
“Another recent work29 optimized mRNA designs and screened them via an experimental platform.”
From Algorithm for optimized mRNA design improves stability and immunogenicity (2023) · cites this paper as [29]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Cycloheximide concentration differs by a factor of one million
MinorThe harvest protocol specifies 100 g/mL cycloheximide, whereas the immediately preceding treatment and the lysis buffer specify 100 μg/mL.
“cells were washed, trypsinized and harvested using PBS, trypsin, and culture media containing 100 g/mL cycloheximide.”
“Cell culture media was replaced with cycloheximide (MilliporeSigma, C7698–1G) containing media at 100ug/mL.”
Degradation-fit equation predicts increasing intact RNA
MinorThe stated function approaches zero as time approaches zero and increases toward A as time passes. That contradicts the stated normalization, which makes the fraction intact equal to 1 at zero hours, and the described degradation time course.
“Fi=Ae−τ/t Where Fi is an array of fraction intact values across multiple time points, A is the amplitude of the exponential decay function, τ is the time constant, and t is an array of time points in hours.”
“FractionIntacti=NormalizedAreaiNormalizedArea0hours”
RT-qPCR input RNA amounts conflict
MinorThe same RT-qPCR methods paragraph gives 0.5 mg and 100-200 ng as the amount of RNA converted to cDNA with iScript Supermix, without distinguishing them as separate procedures.
“0.5 mg of RNA was converted to cDNA using iScript Supermix (Bio-Rad, 1708840).”
“cDNA was synthesized from 100–200 ng of total RNA using iScript Supermix (Bio-Rad, 1708840) containing random hexamer primers”
Cites
Fast gapped-read alignment with Bowtie 2
Langmead, B., & Salzberg, S. L. (2012) · Nature Methods · doi:10.1038/nmeth.1923 · Cited by 56,400 · see citing works
Cutadapt removes adapter sequences from high-throughput sequencing reads
Martin, M. (2011) · EMBnet.journal · doi:10.14806/ej.17.1.200 · Cited by 33,889 · see citing works
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592 · see citing works
Self-citationEfficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119 · see citing works
Global quantification of mammalian gene expression control
Schwanhäusser, B., Busse, D., Li, N., Dittmar, G., Schuchhardt, J., Wolf, J., Chen, W., & Selbach, M. (2011) · Nature · doi:10.1038/nature10098 · Cited by 6,566 · see citing works
Characteristics of SARS-CoV-2 and COVID-19
Hu, B., Guo, H., Zhou, P., & Shi, Z.-L. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-020-00459-7 · Cited by 5,291 · see citing works
Lorenz, R., Bernhart, S. H., Höner zu Siederdissen, C., Tafer, H., Flamm, C., Stadler, P. F., & Hofacker, I. L. (2011) · Algorithms for Molecular Biology · doi:10.1186/1748-7188-6-26 · Cited by 5,098 · see citing works
An analysis of 5'-noncoding sequences from 699 vertebrate messenger RNAs
Kozak, M. (1987) · Nucleic Acids Research · doi:10.1093/nar/15.20.8125 · Cited by 5,090 · see citing works
mRNA vaccines — a new era in vaccinology
Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.243 · Cited by 4,667 · see citing works
Sharp, P. M., & Li, W.-H. (1987) · Nucleic Acids Research · doi:10.1093/nar/15.3.1281 · Cited by 3,992 · see citing works
The scanning model for translation: an update.
Kozak, M. (1989) · The Journal of Cell Biology · doi:10.1083/jcb.108.2.229 · Cited by 3,485 · see citing works
Karikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005) · Immunity · doi:10.1016/j.immuni.2005.06.008 · Cited by 2,728 · see citing works
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
Sahin, U., Derhovanessian, E., Miller, M., Kloke, B.-P., Simon, P., Löwer, M., Bukur, V., Tadmor, A. D., Luxemburger, U., Schrörs, B., et al. (2017) · Nature · doi:10.1038/nature23003 · Cited by 2,488 · see citing works
mRNA-based therapeutics--developing a new class of drugs
Sahin, U., Karikó, K., & Türeci, Ö. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4278 · Cited by 2,474 · see citing works
5'-Triphosphate RNA Is the Ligand for RIG-I
Hornung, V., Ellegast, J., Kim, S., Brzózka, K., Jung, A., Kato, H., Poeck, H., Akira, S., Conzelmann, K.-K., Schlee, M., et al. (2006) · Science · doi:10.1126/science.1132505 · Cited by 2,474 · see citing works
The Architecture of SARS-CoV-2 Transcriptome
Kim, D., Lee, J.-Y., Yang, J.-S., Kim, J. W., Kim, V. N., & Chang, H. (2020) · Cell · doi:10.1016/j.cell.2020.04.011 · Cited by 2,123 · see citing works
Self-citationRNAstructure: software for RNA secondary structure prediction and analysis
Reuter, J. S., & Mathews, D. H. (2010) · BMC Bioinformatics · doi:10.1186/1471-2105-11-129 · Cited by 1,975 · see citing works
Karikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930 · see citing works
cocor: A Comprehensive Solution for the Statistical Comparison of Correlations
Diedenhofen, B., & Musch, J. (2015) · PLOS ONE · doi:10.1371/journal.pone.0121945 · Cited by 1,919 · see citing works
SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness
Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., et al. (2020) · Nature · doi:10.1038/s41586-020-2622-0 · Cited by 1,615 · see citing works
Engineered Luciferase Reporter from a Deep Sea Shrimp Utilizing a Novel Imidazopyrazinone Substrate
Hall, M. P., Unch, J., Binkowski, B. F., Valley, M. P., Butler, B. L., Wood, M. G., Otto, P., Zimmerman, K., Vidugiris, G. J. A., Machleidt, T., et al. (2012) · ACS Chemical Biology · doi:10.1021/cb3002478 · Cited by 1,588 · see citing works
A unifying model for mTORC1-mediated regulation of mRNA translation
Thoreen, C. C., Chantranupong, L., Keys, H. R., Wang, T., Gray, N. S., & Sabatini, D. M. (2012) · Nature · doi:10.1038/nature11083 · Cited by 1,477 · see citing works
The translational landscape of mTOR signalling steers cancer initiation and metastasis
Hsieh, A. C., Liu, Y., Edlind, M. P., Ingolia, N. T., Janes, M. R., Sher, A., Shi, E. Y., Stumpf, C. R., Christensen, C., Bonham, M. J., et al. (2012) · Nature · doi:10.1038/nature10912 · Cited by 1,313 · see citing works
The highways and byways of mRNA decay
Garneau, N. L., Wilusz, J., & Wilusz, C. J. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2104 · Cited by 1,294 · see citing works
From unwinding to clamping — the DEAD box RNA helicase family
Linder, P., & Jankowsky, E. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3154 · Cited by 1,177 · see citing works
Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery
Kowalski, P. S., Rudra, A., Miao, L., & Anderson, D. G. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.02.012 · Cited by 1,127 · see citing works
Functional 5′ UTR mRNA structures in eukaryotic translation regulation and how to find them
Leppek, K., Das, R., & Barna, M. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.103 · Cited by 949 · see citing works
Self-citationCodon optimality, bias and usage in translation and mRNA decay
Hanson, G., & Coller, J. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.91 · Cited by 825 · see citing works
In vivo genome-wide profiling of RNA secondary structure reveals novel regulatory features
Ding, Y., Tang, Y., Kwok, C. K., Zhang, Y., Bevilacqua, P. C., & Assmann, S. M. (2014) · Nature · doi:10.1038/nature12756 · Cited by 775 · see citing works
Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation
Anderson, B. R., Muramatsu, H., Nallagatla, S. R., Bevilacqua, P. C., Sansing, L. H., Weissman, D., & Karikó, K. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq347 · Cited by 682 · see citing works
RNA motif discovery by SHAPE and mutational profiling (SHAPE-MaP)
Siegfried, N. A., Busan, S., Rice, G. M., Nelson, J. A. E., & Weeks, K. M. (2014) · Nature Methods · doi:10.1038/nmeth.3029 · Cited by 662 · see citing works
Li, Y., & Breaker, R. R. (1999) · Journal of the American Chemical Society · doi:10.1021/ja990592p · Cited by 587 · see citing works
NanoLuc: A Small Luciferase Is Brightening Up the Field of Bioluminescence
England, C. G., Ehlerding, E. B., & Cai, W. (2016) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6b00112 · Cited by 585 · see citing works
mRNA structure regulates protein expression through changes in functional half-life
Mauger, D. M., Cabral, B. J., Presnyak, V., Su, S. V., Reid, D. W., Goodman, B., Link, K., Khatwani, N., Reynders, J., Moore, M. J., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1908052116 · Cited by 555 · see citing works
Mayr, C. (2019) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a034728 · Cited by 519 · see citing works
Addressing the Cold Reality of mRNA Vaccine Stability
Crommelin, D. J. A., Anchordoquy, T. J., Volkin, D. B., Jiskoot, W., & Mastrobattista, E. (2021) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2020.12.006 · Cited by 517 · see citing works
Thess, A., Grund, S., Mui, B. L., Hope, M. J., Baumhof, P., Fotin-Mleczek, M., & Schlake, T. (2015) · Molecular Therapy · doi:10.1038/mt.2015.103 · Cited by 513 · cited 1× · see citing works
“CAI was calculated as the geometric mean of the relative usage frequency of codons along the length of the coding region, as previously reported46 (9):”
MethodAlgorithm for Optimized mRNA Design Improves Stability and Immunogenicity
Zhang, H., Zhang, L., Lin, A., Xu, C., Li, Z., Liu, K., Liu, B., Ma, X., Zhao, F., Yao, W., et al. (2020) · arXiv · doi:10.48550/arxiv.2004.10177 · Cited by 511
Ribosome collisions trigger general stress responses to regulate cell fate
Wu, C. C.-C., Peterson, A. F., Zinshteyn, B., Regot, S., & Green, R. (2020) · Cell · doi:10.1016/j.cell.2020.06.006 · Cited by 503 · see citing works
The promise of mRNA vaccines: a biotech and industrial perspective
Jackson, N. A. C., Kester, K. E., Casimiro, D., Gurunathan, S., & DeRosa, F. (2020) · npj Vaccines · doi:10.1038/s41541-020-0159-8 · Cited by 498 · cited 1× · see citing works
“2; Thermo Fisher Scientific-Gibco 20012027) at 50 °C without added MgCl2; and (4) PBS (pH 7.”
BackgroundmRNA Helicase Activity of the Ribosome
Takyar, S. S., Hickerson, R. P., & Noller, H. F. (2005) · Cell · doi:10.1016/j.cell.2004.11.042 · Cited by 497 · see citing works
A triple helix stabilizes the 3′ ends of long noncoding RNAs that lack poly(A) tailsPreprint
Wilusz, J. E., JnBaptiste, C. K., Lu, L. Y., Kuhn, C., Joshua‐Tor, L., & Sharp, P. A. (2012) · Genes & Development · doi:10.1101/gad.204438.112 · Cited by 487 · see citing works
Rate-Limiting Steps in Yeast Protein Translation
Shah, P., Ding, Y., Niemczyk, M., Kudla, G., & Plotkin, J. B. (2013) · Cell · doi:10.1016/j.cell.2013.05.049 · Cited by 463 · see citing works
DMS-MaPseq for genome-wide or targeted RNA structure probing in vivo
Zubradt, M. M., Gupta, P., Persad, S., Lambowitz, A. M., Weissman, J. S., & Rouskin, S. (2016) · Nature Methods · doi:10.1038/nmeth.4057 · Cited by 460 · see citing works
Human 5′ UTR design and variant effect prediction from a massively parallel translation assay
Sample, P. J., Wang, B., Reid, D. W., Presnyak, V., McFadyen, I. J., Morris, D. R., & Seelig, G. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0164-5 · Cited by 442 · see citing works
The challenge and prospect of mRNA therapeutics landscape
Weng, Y., Li, C., Yang, T., Hu, B., Zhang, M., Guo, S., Xiao, H., Liang, X.-J., & Huang, Y. (2020) · Biotechnology Advances · doi:10.1016/j.biotechadv.2020.107534 · Cited by 417 · see citing works
Stabilization of RNA stacking by pseudouridine
Davis, D. R. (1995) · Nucleic Acids Research · doi:10.1093/nar/23.24.5020 · Cited by 399 · see citing works
Orlandini von Niessen, A. G., Poleganov, M. A., Rechner, C., Plaschke, A., Kranz, L. M., Fesser, S., Diken, M., Löwer, M., Vallazza, B., Beissert, T., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2018.12.011 · Cited by 365 · see citing works
Matoulkova, E., Michalova, E., Vojtesek, B., & Hrstka, R. (2012) · RNA Biology · doi:10.4161/rna.20231 · Cited by 357 · see citing works
Multi-epitope vaccines: a promising strategy against tumors and viral infections
Zhang, L. (2017) · Cellular and Molecular Immunology · doi:10.1038/cmi.2017.92 · Cited by 352 · see citing works
Control of mammalian translation by mRNA structure near caps
Babendure, J. R., Babendure, J. L., Ding, J.-H., & Tsien, R. Y. (2006) · RNA · doi:10.1261/rna.2309906 · Cited by 339 · see citing works
In-Line Probing Analysis of Riboswitches
Regulski, E. E., & Breaker, R. R. (2008) · Methods In Molecular Biology™ · doi:10.1007/978-1-59745-033-1_4 · Cited by 338 · see citing works
The ribosome uses two active mechanisms to unwind messenger RNA during translation
Qu, X., Wen, J., Lancaster, L., Noller, H. F., Bustamante, C., & Tinoco, I. (2011) · Nature · doi:10.1038/nature10126 · Cited by 327 · see citing works
RNA regulons in Hox 5′ UTRs confer ribosome specificity to gene regulation
Xue, S., Tian, S., Fujii, K., Kladwang, W., Das, R., & Barna, M. (2014) · Nature · doi:10.1038/nature14010 · Cited by 319 · see citing works
Self-citationHuston, N. C., Wan, H., Strine, M. S., Tavares, R. D. C. A., Wilen, C. B., & Pyle, A. M. (2021) · Molecular Cell · doi:10.1016/j.molcel.2020.12.041 · Cited by 318 · see citing works
RNA design rules from a massive open laboratory
Lee, J., Kladwang, W., Lee, M. J., Cantu, D., Azizyan, M., Kim, H., Limpaecher, A., Gaikwad, S. M., Yoon, S., Treuille, A., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1313039111 · Cited by 303 · see citing works
Self-citationGenome-wide mapping of SARS-CoV-2 RNA structures identifies therapeutically-relevant elements
Manfredonia, I., Nithin, C., Ponce-Salvatierra, A., Ghosh, P., Wirecki, T. K., Marinus, T., Ogando, N. S., Snijder, E. J., van Hemert, M. J., Bujnicki, J. M., et al. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa1053 · Cited by 283 · see citing works
Secondary structural ensembles of the SARS-CoV-2 RNA genome in infected cells
Lan, T. C. T., Allan, M. F., Malsick, L. E., Woo, J. Z., Zhu, C., Zhang, F., Khandwala, S., Nyeo, S. S. Y., Sun, Y., Guo, J. U., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28603-2 · Cited by 265 · see citing works
The contribution of pseudouridine to stabilities and structure of RNAs
Kierzek, E., Malgowska, M., Lisowiec, J., Turner, D. H., Gdaniec, Z., & Kierzek, R. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1330 · Cited by 264 · see citing works
Decoding mRNA translatability and stability from the 5′ UTR
Jia, L., Mao, Y., Ji, Q., Dersh, D., Yewdell, J. W., & Qian, S.-B. (2020) · Nature Structural & Molecular Biology · doi:10.1038/s41594-020-0465-x · Cited by 248 · see citing works
Multiple roles of the coding sequence 5′ end in gene expression regulation
Tuller, T., & Zur, H. (2015) · Nucleic Acids Research · doi:10.1093/nar/gku1313 · Cited by 206 · see citing works
3′ Cap-Independent Translation Enhancers of Plant Viruses
Simon, A. E., & Miller, W. A. (2013) · Annual Review of Microbiology · doi:10.1146/annurev-micro-092412-155609 · Cited by 204 · see citing works
Theoretical basis for stabilizing messenger RNA through secondary structure design
Wayment-Steele, H. K., Kim, D. S., Choe, C. A., Nicol, J. J., Wellington-Oguri, R., Watkins, A. M., Sperberg, R. A. P., Huang, P.-S., Participants, E., & Das, R. (2020) · doi:10.1101/2020.08.22.262931 · Cited by 199 · see citing works
Self-citationTheoretical basis for stabilizing messenger RNA through secondary structure design
Wayment-Steele, H. K., Kim, D. S., Choe, C. A., Nicol, J. J., Wellington-Oguri, R., Watkins, A. M., Parra Sperberg, R. A., Huang, P.-S., Participants, E., & Das, R. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab764 · Cited by 197 · see citing works
Self-citationRibosome collisions trigger cis-acting feedback inhibition of translation initiation
Juszkiewicz, S., Slodkowicz, G., Lin, Z., Freire-Pritchett, P., Peak‐Chew, S., & Hegde, R. S. (2020) · eLife · doi:10.7554/elife.60038 · Cited by 170 · see citing works
Hickey, K. L., Dickson, K., Cogan, J. Z., Replogle, J. M., Schoof, M., D’Orazio, K. N., Sinha, N. K., Hussmann, J. A., Jost, M., Frost, A. S., et al. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.07.007 · Cited by 162 · see citing works
High-throughput 5’ UTR engineering for enhanced protein production in non-viral gene therapies
Cao, J., Novoa, E. M., Zhang, Z., Chen, W. C. W., Liu, D., Choi, G. C. G., Wong, A. S. L., Wehrspaun, C., Kellis, M., & Lu, T. K. (2021) · Nature Communications · doi:10.1038/s41467-021-24436-7 · Cited by 159 · see citing works
Leveraging mRNA Sequences and Nanoparticles to Deliver SARS‐CoV‐2 Antigens In Vivo
Zeng, C., Hou, X., Yan, J., Zhang, C., Li, W., Zhao, W., Du, S., & Dong, Y. (2020) · Advanced Materials · doi:10.1002/adma.202004452 · Cited by 152 · see citing works
The 5'-leader of tobacco mosaic virus promotes translation through enhanced recruitment of eIF4F
Gallie, D. (2002) · Nucleic Acids Research · doi:10.1093/nar/gkf457 · Cited by 149 · see citing works
Predicting the sizes of large RNA molecules
Yoffe, A. M., Prinsen, P., Gopal, A., Knobler, C. M., Gelbart, W. M., & Ben-Shaul, A. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0808089105 · Cited by 140 · see citing works
kpLogo: positional k-mer analysis reveals hidden specificity in biological sequences
Wu, X., & Bartel, D. P. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx323 · Cited by 140 · see citing works
Nallagatla, S. R., & Bevilacqua, P. C. (2008) · RNA · doi:10.1261/rna.1007408 · Cited by 137 · see citing works
Gallie, D., Tanguay, R. L., & Leathers, V. L. (1995) · Gene · doi:10.1016/0378-1119(95)00521-7 · Cited by 125 · see citing works
Massively parallel functional annotation of 3′ untranslated regions
Zhao, W., Pollack, J. L., Blagev, D. P., Zaitlen, N., McManus, M. T., & Erle, D. J. (2014) · Nature Biotechnology · doi:10.1038/nbt.2851 · Cited by 125 · see citing works
Holden, K. L., & Harris, E. (2004) · Virology · doi:10.1016/j.virol.2004.08.004 · Cited by 121 · see citing works
A Dengue Virus Serotype 1 mRNA-LNP Vaccine Elicits Protective Immune Responses
Wollner, C. J., Richner, M., Hassert, M., Pinto, A. K., Brien, J. D., & Richner, J. M. (2021) · Journal of Virology · doi:10.1128/jvi.02482-20 · Cited by 119 · see citing works
Control of Translation by the 5′- and 3′-Terminal Regions of the Dengue Virus Genome
Chiu, W.-W., Kinney, R. M., & Dreher, T. W. (2005) · Journal of Virology · doi:10.1128/jvi.79.13.8303-8315.2005 · Cited by 118 · see citing works
Single-cell mRNA transfection studies: Delivery, kinetics and statistics by numbers
Leonhardt, C., Schwake, G., Stögbauer, T. R., Rappl, S., Kuhr, J.-T., Ligon, T. S., & Rädler, J. O. (2014) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2013.11.008 · Cited by 117 · see citing works
Sokoloski, K. J., Dickson, A., Chaskey, E. L., Garneau, N. L., Wilusz, C. J., & Wilusz, J. (2010) · Cell Host & Microbe · doi:10.1016/j.chom.2010.07.003 · Cited by 112 · see citing works
Incarnato, D., Morandi, E., Simon, L. M., & Oliviero, S. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky486 · Cited by 112 · see citing works
Optimization of mRNA untranslated regions for improved expression of therapeutic mRNA
Asrani, K. H., Farelli, J. D., Stahley, M. R., Miller, R. L., Cheng, C. J., Subramanian, R. R., & Brown, J. M. (2018) · RNA Biology · doi:10.1080/15476286.2018.1450054 · Cited by 111 · see citing works
Ciphers and Executioners: How 3′-Untranslated Regions Determine the Fate of Messenger RNAs
Mayya, V. K., & Duchaîne, T. F. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00006 · Cited by 108 · see citing works
Kozak, M. (1994) · Journal of Molecular Biology · doi:10.1016/s0022-2836(05)80019-1 · Cited by 101 · see citing works
Poly(A) leader of eukaryotic mRNA bypasses the dependence of translation on initiation factors
Shirokikh, N. E., & Spirin, A. S. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804940105 · Cited by 98 · see citing works
3′ Cap-independent translation enhancers of positive-strand RNA plant viruses
Nicholson, B. L., & White, K. A. (2011) · Current Opinion in Virology · doi:10.1016/j.coviro.2011.10.002 · Cited by 97 · see citing works
Garneau, N. L., Sokoloski, K. J., Opyrchal, M., Neff, C. P., Wilusz, C. J., & Wilusz, J. (2007) · Journal of Virology · doi:10.1128/jvi.01205-07 · Cited by 76 · see citing works
In vitro analysis of RQC activities provides insights into the mechanism and function of CAT tailing
Osuna, B. A., Howard, C. J., Subheksha, K. C., Frost, A. S., & Weinberg, D. E. (2017) · eLife · doi:10.7554/elife.27949 · Cited by 73 · see citing works
Consistent global structures of complex RNA states through multidimensional chemical mapping
Cheng, C. Y., Chou, F., Kladwang, W., Tian, S., Cordero, P., & Das, R. (2015) · eLife · doi:10.7554/elife.07600 · Cited by 72 · see citing works
Self-citationKaukinen, U. (2002) · Nucleic Acids Research · doi:10.1093/nar/30.2.468 · Cited by 69 · see citing works
The effect of secondary structure on cleavage of the phosphodiester bonds of RNA
Mikkola, S., Kaukinen, U., & Lönnberg, H. (2001) · Cell Biochemistry and Biophysics · doi:10.1385/cbb:34:1:95 · Cited by 67 · see citing works
Penalized Regression with Ordinal Predictors
Gertheiss, J., & Tutz, G. (2009) · International Statistical Review · doi:10.1111/j.1751-5823.2009.00088.x · Cited by 65 · see citing works
Massively Parallel RNA Chemical Mapping with a Reduced Bias MAP-Seq Protocol
Seetin, M. G., Kladwang, W., Bida, J. P., & Das, R. (2014) · Methods in Molecular Biology · doi:10.1007/978-1-62703-667-2_6 · Cited by 63 · see citing works
Self-citationInsights into the secondary structural ensembles of the full SARS-CoV-2 RNA genome in infected cells
Lan, T. C. T., Allan, M. F., Malsick, L. E., Khandwala, S., Nyeo, S. S. Y., Sun, Y., Guo, J. U., Bathe, M., Griffiths, A., & Rouskin, S. (2020) · doi:10.1101/2020.06.29.178343 · Cited by 62
Arginase I mRNA therapy – a novel approach to rescue arginase 1 enzyme deficiency
Asrani, K. H., Cheng, L., Cheng, C. J., & Subramanian, R. R. (2018) · RNA Biology · doi:10.1080/15476286.2018.1475178 · Cited by 58 · see citing works
Gene- and Species-Specific Hox mRNA Translation by Ribosome Expansion Segments
Leppek, K., Fujii, K., Quade, N., Susanto, T. T., Boehringer, D., Lenarčič, T., Xue, S., Genuth, N. R., Ban, N., & Barna, M. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.10.023 · Cited by 56 · see citing works
Self-citationAlgorithms for efficiently collapsing reads with Unique Molecular Identifiers
Liu, D. (2019) · PeerJ · doi:10.7717/peerj.8275 · Cited by 54 · see citing works
Patel, M., Siegel, A. J., & Berry, J. O. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m604162200 · Cited by 53 · see citing works
Standardization of RNA Chemical Mapping Experiments
Kladwang, W., Mann, T. H., Becka, A. J., Tian, S., Kim, H., Yoon, S., & Das, R. (2014) · Biochemistry · doi:10.1021/bi5003426 · Cited by 53 · see citing works
Self-citationIdentification of a grpE Heat-shock Gene Homolog in the Archeon Methanosarcina mazie
de Macario, E. C., Dugan, C. B., & Macario, A. J. L. (1994) · Journal of Molecular Biology · doi:10.1006/jmbi.1994.1422 · Cited by 48 · see citing works
Human 5′ UTR design and variant effect prediction from a massively parallel translation assayPreprint
Sample, P. J., Wang, B., Reid, D. W., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/310375 · Cited by 47 · see citing works
Ferizi, M., Aneja, M. K., Balmayor, E. R., Badieyan, Z. S., Mykhaylyk, O. M., Rudolph, C., & Plank, C. (2016) · Scientific Reports · doi:10.1038/srep39149 · Cited by 46 · see citing works
Manfredonia, I., & Incarnato, D. (2020) · Biochemical Society Transactions · doi:10.1042/bst20200670 · Cited by 46 · see citing works
Sultana, N., Hadas, Y., Sharkar, M. T. K., Kaur, K., Magadum, A., Kurian, A. A., Hossain, N., Alburquerque, B., Ahmed, S. M. M., Chepurko, E., et al. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.03.019 · Cited by 45 · see citing works
Eisenhut, P., Mebrahtu, A., Moradi Barzadd, M., Thalén, N., Klanert, G., Weinguny, M., Sandegren, A., Su, C., Hatton, D., Borth, N., et al. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa847 · Cited by 38 · see citing works
Terai, G., Kamegai, S., & Asai, K. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btv678 · Cited by 36 · see citing works
Natural Selection and Algorithmic Design of mRNA
Cohen, B., & Skiena, S. (2003) · Journal of Computational Biology · doi:10.1089/10665270360688101 · Cited by 35 · see citing works
HiTRACE-Web: an online tool for robust analysis of high-throughput capillary electrophoresis
Kim, H., Cordero, P., Das, R., & Yoon, S. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt501 · Cited by 31 · see citing works
Self-citationLeveraging mRNAs sequences to express SARS-CoV-2 antigens in vivoPreprint
Zeng, C., Hou, X., Yan, J., Zhang, C., Li, W., Zhao, W., Du, S., & Dong, Y. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.04.01.019877 · Cited by 29 · see citing works
Palusa, S. G., Ndaluka, C., Bowen, R. A., Wilusz, C. J., & Wilusz, J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033561 · Cited by 25 · see citing works
Updates to the RNA mapping database (RMDB), version 2
Yesselman, J. D., Tian, S., Liu, X., Shi, L., Li, J. B., & Das, R. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx873 · Cited by 22 · see citing works
Self-citationMie, M., Shimizu, S., Takahashi, F., & Kobatake, E. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.05.173 · Cited by 11 · see citing works
LinearDesign: Efficient Algorithms for Optimized mRNA Sequence DesignPreprint
Zhang, H., Zhang, L., Li, Z., Liu, K., Liu, B., Mathews, D. H., & Huang, L. (2020) · arXiv (Cornell University) · Cited by 8 · see citing works
Wang, H., Yu, Y., Liu, T., Pan, Y., Yan, S., & Wang, Y. (2015) · SpringerPlus · doi:10.1186/s40064-015-0973-z · Cited by 7 · see citing works
A mRNA-LNP vaccine against Dengue Virus elicits robust, serotype-specific immunity
Wollner, C. J., Richner, M., Hassert, M. A., Pinto, A. K., Brien, J. D., & Richner, J. M. (2021) · doi:10.1101/2021.01.05.425517 · Cited by 6 · see citing works
High-Throughput 5’ UTR Engineering for Enhanced Protein Production in Non-Viral Gene Therapies
Cao, J., Novoa, E. M., Zhang, Z., Chen, W. C. W., Liu, D., Choi, G. C. G., Wong, A. S. L., Wehrspaun, C., Kellis, M., & Lu, T. K. (2020) · doi:10.1101/2020.03.24.006486 · Cited by 3
Flagged first, then by citations
2 of the 117 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
mRNA-based therapeutics: powerful and versatile tools to combat diseases
Qin, S., Tang, X., Chen, Y., Chen, K., Fan, N., Xiao, W., Zheng, Q., Li, G., Teng, Y., Wu, M., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01007-w · Cited by 801 · see citing works
Mendes, B. B., Conniot, J., Avital, A., Yao, D., Jiang, X., Zhou, X., Sharf-Pauker, N., Xiao, Y., Adir, O., Liang, H., et al. (2022) · Nature Reviews Methods Primers · doi:10.1038/s43586-022-00104-y · Cited by 719 · see citing works
The landscape of mRNA nanomedicine
Huang, X., Kong, N., Zhang, X., Cao, Y., Langer, R., & Tao, W. (2022) · Nature Medicine · doi:10.1038/s41591-022-02061-1 · Cited by 511 · see citing works
Algorithm for optimized mRNA design improves stability and immunogenicity
Zhang, H., Zhang, L., Lin, A., Xu, C., Li, Z., Liu, K., Liu, B., Ma, X., Zhao, F., Jiang, H., et al. (2023) · Nature · doi:10.1038/s41586-023-06127-z · Cited by 498 · see citing works
mRNA vaccines for infectious diseases — advances, challenges and opportunities
Pardi, N., & Krammer, F. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01042-y · Cited by 246 · see citing works
The Storage and In-Use Stability of mRNA Vaccines and Therapeutics: Not A Cold Case
Blenke, E. O., Örnskov, E., Schöneich, C., Nilsson, G. Å., Volkin, D. B., Mastrobattista, E., Almarsson, Ö., & Crommelin, D. J. A. (2022) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2022.11.001 · Cited by 214 · see citing works
Nucleic acid drugs: recent progress and future perspectives
Sun, X., Setrerrahmane, S., Li, C., Hu, J., & Xu, H. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02035-4 · Cited by 202 · see citing works
Theoretical basis for stabilizing messenger RNA through secondary structure design
Wayment-Steele, H. K., Kim, D. S., Choe, C. A., Nicol, J. J., Wellington-Oguri, R., Watkins, A. M., Parra Sperberg, R. A., Huang, P.-S., Participants, E., & Das, R. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab764 · Cited by 197 · see citing works
Self-citationChemically Modified Platforms for Better RNA Therapeutics
Shi, Y., Zhen, X., Zhang, Y., Li, Y., Koo, S., Saiding, Q., Kong, N., Liu, G., Chen, W., & Tao, W. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00611 · Cited by 184 · see citing works
Nanotechnology-based mRNA vaccines
Chen, S., Huang, X., Xue, Y., Álvarez‐Benedicto, E., Shi, Y., Chen, W., Koo, S., Siegwart, D. J., Dong, Y., & Tao, W. (2023) · Nature Reviews Methods Primers · doi:10.1038/s43586-023-00246-7 · Cited by 172 · see citing works
Factors Affecting Stability of RNA – Temperature, Length, Concentration, pH, and Buffering Species
Chheda, U., Pradeepan, S., Esposito, E. A., Strezsak, S. R., Fernandez‐Delgado, O., & Kranz, J. K. (2023) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2023.11.023 · Cited by 166 · see citing works
Minnaert, A.-K., Vanluchene, H., Verbeke, R., Lentacker, I., De Smedt, S. C., Raemdonck, K., Sanders, N. N., & Remaut, K. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113900 · Cited by 157 · see citing works
The genetic and biochemical determinants of mRNA degradation rates in mammals
Agarwal, V., & Kelley, D. R. (2022) · Genome Biology · doi:10.1186/s13059-022-02811-x · Cited by 155 · see citing works
RNA secondary structure packages evaluated and improved by high-throughput experiments
Wayment-Steele, H. K., Kladwang, W., Strom, A. I., Lee, J., Treuille, A., Becka, A. J., Participants, E., & Das, R. (2022) · Nature Methods · doi:10.1038/s41592-022-01605-0 · Cited by 154 · see citing works
Self-citationOptimization of storage conditions for lipid nanoparticle-formulated self-replicating RNA vaccines
Kim, B., Hosn, R. R., Remba, T. K., Yun, D. S., Li, N., Abraham, W. D., Melo, M. B., Cortés, M., Li, B., Zhang, Y., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.11.022 · Cited by 154 · see citing works
Tailor made: the art of therapeutic mRNA design
Metkar, M., Pepin, C. S., & Moore, M. J. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00827-x · Cited by 153 · see citing works
The use of RNA-based treatments in the field of cancer immunotherapy
Chehelgerdi, M., & Chehelgerdi, M. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01807-w · Cited by 146 · see citing works
A 5′ UTR language model for decoding untranslated regions of mRNA and function predictions
Chu, Y., Yu, D., Li, Y., Huang, K., Shen, Y., Cong, L., Zhang, J. Y., & Wang, M. (2024) · Nature Machine Intelligence · doi:10.1038/s42256-024-00823-9 · Cited by 143 · see citing works
Engineered tRNAs suppress nonsense mutations in cells and in vivo
Albers, S., Allen, E. C., Bharti, N., Davyt, M., Joshi, D., Pérez‐García, C. G., Santos, L. A., Mukthavaram, R., Delgado-Toscano, M. A., Molina, B., et al. (2023) · Nature · doi:10.1038/s41586-023-06133-1 · Cited by 140 · see citing works
Direct in vivo CAR T cell engineering
Short, L., Holt, R. A., Cullis, P. R., & Evgin, L. (2024) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2024.03.004 · Cited by 134 · see citing works
Branched chemically modified poly(A) tails enhance the translation capacity of mRNA
Chen, H., Liu, D., Guo, J., Aditham, A. J., Zhou, Y., Tian, J., Luo, S., Ren, J., Hsu, A., Huang, J., et al. (2024) · Nature Biotechnology · doi:10.1038/s41587-024-02174-7 · Cited by 129 · see citing works
Quality by Design for enabling RNA platform production processes
Daniel, S., Kis, Z., Kontoravdi, C., & Shah, N. (2022) · Trends in biotechnology · doi:10.1016/j.tibtech.2022.03.012 · Cited by 128 · see citing works
Machine Learning for Designing Next-Generation mRNA Therapeutics
Castillo-Hair, S. M., & Seelig, G. (2021) · Accounts of Chemical Research · doi:10.1021/acs.accounts.1c00621 · Cited by 119 · see citing works
Translation and mRNA Stability Control
Wu, Q., & Bazzini, A. (2023) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-052621-091808 · Cited by 117 · see citing works
ADAR1-mediated RNA editing of SCD1 drives drug resistance and self-renewal in gastric cancer
Wong, T. L., Loh, J.-J., Lu, S., Yan, H. H. N., Siu, H. C., Ren, X., Chan, D., Kam, M. J., Zhou, L., Tong, M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38581-8 · Cited by 115 · see citing works
The advent of clinical self-amplifying RNA vaccines
Casmil, I. C., Jin, J., Won, E.-J., Huang, C., Liao, S., Cha‐Molstad, H., & Blakney, A. K. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.060 · Cited by 105 · see citing works
Sato, K., & Hamada, M. (2023) · Briefings in Bioinformatics · doi:10.1093/bib/bbad186 · Cited by 101 · see citing works
Advancements of in vitro transcribed mRNA (IVT mRNA) to enable translation into the clinics
Kang, D. D., Li, H., & Dong, Y. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114961 · Cited by 100 · see citing works
Optimizing 5’UTRs for mRNA-delivered gene editing using deep learning
Castillo-Hair, S., Fedak, S., Wang, B., Linder, J., Havens, K., Certo, M., & Seelig, G. (2024) · Nature Communications · doi:10.1038/s41467-024-49508-2 · Cited by 98 · see citing works
Fei, Y., Yu, X., Liu, P., Ren, H., Wei, T., & Cheng, Q. (2024) · Advanced Materials · doi:10.1002/adma.202409812 · Cited by 94 · see citing works
mRNA Vaccine Development for Emerging Animal and Zoonotic Diseases
Le, T., Sun, C., Chang, J., Zhang, G., & Yin, X. (2022) · Viruses · doi:10.3390/v14020401 · Cited by 93 · see citing works
Frameworks for transformational breakthroughs in RNA-based medicines
Androsavich, J. R. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00943-2 · Cited by 93 · see citing works
Chemical Modifications of mRNA Ends for Therapeutic Applications
Warminski, M., Mamot, A., Depaix, A., Kowalska, J., & Jemielity, J. (2023) · Accounts of Chemical Research · doi:10.1021/acs.accounts.3c00442 · Cited by 91 · see citing works
mRNA nanodelivery systems: targeting strategies and administration routes
Yuan, M., Han, Z., Liang, Y., Sun, Y., He, B., Chen, W., & Fan, L. (2023) · Biomaterials Research · doi:10.1186/s40824-023-00425-3 · Cited by 90 · see citing works
Eliciting antitumor immunity via therapeutic cancer vaccines
Peng, K., Zhao, X., Fu, Y., & Liang, Y. (2025) · Cellular and Molecular Immunology · doi:10.1038/s41423-025-01316-4 · Cited by 89 · see citing works
Advanced technologies for the development of infectious disease vaccines
Gupta, A., Rudra, A., Reed, K., Langer, R., & Anderson, D. G. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01041-z · Cited by 85 · see citing works
mRNA vaccine sequence and structure design and optimization: Advances and challenges
Jin, L., Zhou, Y., Zhang, S., & Chen, S. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.108015 · Cited by 85 · see citing works
Deep generative models design mRNA sequences with enhanced translational capacity and stability
Zhang, H., Liu, H., Xu, Y., Huang, H., Liu, Y., Wang, J., Qin, Y., Wang, H., Ma, L., Xun, Z., et al. (2025) · Science · doi:10.1126/science.adr8470 · Cited by 84 · see citing works
Nucleic acid therapeutics: Past, present, and future
Naeem, S., Zhang, J., Zhang, Y., & Wang, Y. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102440 · Cited by 78 · see citing works
Computational biology and artificial intelligence in mRNA vaccine design for cancer immunotherapy
İmani, S., Li, X., Chen, K., Maghsoudloo, M., Kaboli, P. J., Hashemi, M., Khoushab, S., & Li, X. (2025) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2024.1501010 · Cited by 78 · see citing works
Zhang, H., & Barz, M. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.02.055 · Cited by 77 · see citing works
Reversible 2′-OH acylation enhances RNA stability
Fang, L., Xiao, L., Jun, Y. W., Onishi, Y., & Kool, E. T. (2023) · Nature Chemistry · doi:10.1038/s41557-023-01246-6 · Cited by 76 · see citing works
mRNA – A game changer in regenerative medicine, cell-based therapy and reprogramming strategies
Chabanovska, O., Galow, A.-M., David, R., & Lemcke, H. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114002 · Cited by 76 · see citing works
Scarpini, S., Morigi, F., Betti, L., Dondi, A., Biagi, C., & Lanari, M. (2021) · Vaccines · doi:10.3390/vaccines9060551 · Cited by 74 · see citing works
Jia, W., Wu, Y., Xie, Y., Yu, M., & Chen, Y. (2025) · Advanced Materials · doi:10.1002/adma.202413603 · Cited by 74 · see citing works
Gene editing therapeutics based on mRNA delivery
Popovitz, J., Sharma, R. K., Hoshyar, R., Kim, B. S., Murthy, N., & Lee, K. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.115026 · Cited by 73 · see citing works
Review of machine learning for lipid nanoparticle formulation and process development
Dorsey, P. J., Lau, C. L., Chang, T., Doerschuk, P. C., & D’Addio, S. M. (2024) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2024.09.015 · Cited by 73 · see citing works
mRNA Therapeutic Modalities Design, Formulation and Manufacturing under Pharma 4.0 Principles
Ouranidis, A., Vavilis, T., Mandala, E., Davidopoulou, C., Stamoula, Ε., Markopoulou, C. K., Karagianni, A., & Kachrimanis, K. (2021) · Biomedicines · doi:10.3390/biomedicines10010050 · Cited by 72 · see citing works
The mRNA Vaccine Revolution: COVID-19 Has Launched the Future of Vaccinology
Ye, Z., Harmon, J., Ni, W., Li, Y., Wich, D., & Xu, Q. (2023) · ACS Nano · doi:10.1021/acsnano.2c12584 · Cited by 71 · see citing works
Bicknell, A. A., Reid, D. W., Licata, M. C., Jones, A. K., Cheng, Y. M., Li, M., Hsiao, C. J., Pepin, C. S., Metkar, M., Levdansky, Y., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114098 · Cited by 68 · see citing works
Codon-optimization in gene therapy: promises, prospects and challenges
Paremskaia, A. I., Kogan, A. A., Murashkina, A., Naumova, D. A., Satish, A., Abramov, I. S., Feoktistova, S. G., Mityaeva, O. N., Deviatkin, A. A., & Volchkov, P. (2024) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2024.1371596 · Cited by 66 · see citing works
Xie, S., Raman, S. R. S., Ni, C., Wang, M., Yang, M., & Kulkarni, J. P. (2022) · IEEE Journal of Solid-State Circuits · doi:10.1109/jssc.2022.3176610 · Cited by 65 · see citing works
CodonBERT large language model for mRNA vaccinesPreprint
Li, S., Moayedpour, S., Li, R., Bailey, M., Riahi, S., Kogler-Anele, L., Miladi, M., Miner, J. C., Pertuy, F., Zheng, D., et al. (2024) · Genome Research · doi:10.1101/gr.278870.123 · Cited by 64 · see citing works
mRNA-Based Therapeutics in Cancer Treatment
Sun, H., Zhang, Y., Wang, G., Yang, W., & Xu, Y. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020622 · Cited by 63 · see citing works
Nebulised delivery of RNA formulations to the lungs: From aerosol to cytosol
Neary, M. T., Mulder, L. M., Kowalski, P. S., MacLoughlin, R. J., Crean, A. M., & Ryan, K. B. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.12.012 · Cited by 62 · see citing works
Understanding the impact of in vitro transcription byproducts and contaminants
Lenk, R., Kleindienst, W., Szabó, G. T., Baiersdörfer, M., Boros, G., Keller, J. M., Mahiny, A. J., & Vlatkovic, I. (2024) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2024.1426129 · Cited by 63 · see citing works
Overcoming Pharmaceutical Bottlenecks for Nucleic Acid Drug Development
Lu, M., Xing, H., Zheng, A., Huang, Y., & Liang, X. (2023) · Accounts of Chemical Research · doi:10.1021/acs.accounts.2c00464 · Cited by 58 · see citing works
A Review on the Stability Challenges of Advanced Biologic Therapeutics
Sarvepalli, S., Pasika, S. R., Verma, V., Thumma, A., Bolla, S., Nukala, P. K., Butreddy, A., & Bolla, P. K. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17050550 · Cited by 58 · see citing works
Messenger RNA vaccines for cancer immunotherapy: progress promotes promise
Huff, A. L., Jaffee, E. M., & Zaidi, N. (2022) · Journal of Clinical Investigation · doi:10.1172/jci156211 · Cited by 56 · see citing works
Deep learning models for predicting RNA degradation via dual crowdsourcing
Wayment-Steele, H. K., Kladwang, W., Watkins, A. M., Kim, D. S., Tunguz, B., Reade, W., Demkin, M., Romano, J., Wellington-Oguri, R., Nicol, J. J., et al. (2022) · Nature Machine Intelligence · doi:10.1038/s42256-022-00571-8 · Cited by 56 · see citing works
Self-citationOptimized circular RNA vaccines for superior cancer immunotherapy
Yu, H., Wen, Y., Yu, W., Lu, L., Yang, Y., Liu, C., Hu, Z., Fang, Z., & Huang, S. (2024) · Theranostics · doi:10.7150/thno.104698 · Cited by 52 · see citing works
Exogenous RNA surveillance by proton-sensing TRIM25
Kim, M., Pyo, Y., Hyun, S., Jeong, M., Choi, Y., & Kim, V. N. (2025) · Science · doi:10.1126/science.ads4539 · Cited by 49 · see citing works
Computational design of mRNA vaccines
Kim, Y.-A., Mousavi, K., Yazdi, A. K., Zwierzyna, M., Cardinali, M., Fox, D. M., Peel, T., Coller, J., Aggarwal, K., & Maruggi, G. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.07.024 · Cited by 47 · see citing works
RNAdegformer: accurate prediction of mRNA degradation at nucleotide resolution with deep learning
He, S., Gao, B., Sabnis, R., & Sun, Q. (2023) · Briefings in Bioinformatics · doi:10.1093/bib/bbac581 · Cited by 46 · see citing works
Polyplex designs for improving the stability and safety of RNA therapeutics
Uchida, S., Lau, C. Y. J., Oba, M., & Miyata, K. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114972 · Cited by 46 · see citing works
Cytoplasmic mRNA decay and quality control machineries in eukaryotes
Dowdle, M. E., & Lykke‐Andersen, J. (2025) · Nature Reviews Genetics · doi:10.1038/s41576-024-00810-1 · Cited by 46 · see citing works
Tanaka, H., Hagiwara, S., Shirane, D., Yamakawa, T., Sato, Y., Matsumoto, C., Ishizaki, K., Hishinuma, M., Chida, K., Sasaki, K., et al. (2023) · ACS Nano · doi:10.1021/acsnano.2c10501 · Cited by 44 · see citing works
Rohde, C. M., Lindemann, C., Giovanelli, M. A., Sellers, R. S., Diekmann, J., Choudhary, S., Ramaiah, L., Vogel, A. B., Chervona, Y., Muik, A., et al. (2023) · Vaccines · doi:10.3390/vaccines11020417 · Cited by 44 · see citing works
Development of Thermally Stable mRNA-LNP Delivery Systems: Current Progress and Future Prospects
Kafle, U., Truong, H. Q., Cao, T. G. N., & Meng, F. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00826 · Cited by 44 · see citing works
Self-citationCurrent Analytical Strategies for mRNA-Based Therapeutics
Camperi, J., Chatla, K., Freund, E. C., Galan, C., Lippold, S., & Guilbaud, A. (2025) · Molecules · doi:10.3390/molecules30071629 · Cited by 43 · see citing works
Zhao, Y., & Wang, H. (2025) · Briefings in Bioinformatics · doi:10.1093/bib/bbaf263 · Cited by 40 · see citing works
Generative and predictive neural networks for the design of functional RNA molecules
Riley, A. T., Robson, J. M., Ulanova, A., & Green, A. A. (2025) · Nature Communications · doi:10.1038/s41467-025-59389-8 · Cited by 39 · see citing works
Pothoulakis, G., Nguyen, M. T. A., & Andersen, E. S. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac470 · Cited by 38 · see citing works
Li, Y., Wang, F., Yang, J., Han, Z., Chen, L., Jiang, W., Zhou, H., Li, T., Tang, Z., Deng, J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-64894-x · Cited by 37 · see citing works
Mo, O., Zhang, Z., Cheng, X., Zhu, L., Zhang, K., Zhang, N., Li, J., Li, H., Fan, S., Li, X., et al. (2025) · Nucleic Acids Research · doi:10.1093/nar/gkaf410 · Cited by 36 · see citing works
Nanoformulations targeting immune cells for cancer therapy: mRNA therapeutics
Yang, W., Cao, J., Cheng, H., Chen, L., Yu, M., Chen, Y., & Cui, X. (2022) · Bioactive Materials · doi:10.1016/j.bioactmat.2022.11.014 · Cited by 36 · see citing works
Ribonanza: deep learning of RNA structure through dual crowdsourcingPreprint
He, S., Huang, R., Townley, J., Kretsch, R. C., Karagianes, T. G., Cox, D. B. T., Blair, H., Penzar, D., Vyaltsev, V., Aristova, E., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.02.24.581671 · Cited by 36 · see citing works
Self-citationNon-viral nucleic acid delivery approach: A boon for state-of-the-art gene delivery
Sahu, K. K., Pradhan, M., Singh, D., Singh, M. R., & Yadav, D. K. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.104152 · Cited by 35 · see citing works
Vaccine development using artificial intelligence and machine learning: A review
Asediya, V., Anjaria, P. A., Mathakiya, R. A., KORINGA, P. G., Nayak, J. B., Bisht, D., Fulmali, D., Patel, V. A., & Desai, D. N. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.136643 · Cited by 35 · see citing works
Engineering Lipid Nanoparticles for mRNA Immunotherapy
Zwolsman, R. C., Darwish, Y. B., Kluza, E., & van der Meel, R. (2025) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.70007 · Cited by 35 · see citing works
Preformed Vesicle Approach to LNP Manufacturing Enhances Retinal mRNA Delivery
Eygeris, Y., Henderson, M. I., Curtis, A. G., Jozić, A., Stoddard, J., Reynaga, R., Chirco, K. R., Su, G., Neuringer, M., Lauer, A. K., et al. (2024) · Small · doi:10.1002/smll.202400815 · Cited by 34 · see citing works
CodonBERT: Large Language Models for mRNA design and optimizationPreprint
Li, S., Moayedpour, S., Li, R., Bailey, M., Riahi, S., Kogler-Anele, L., Miladi, M., Miner, J. C., Zheng, D., Wang, J., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.09.09.556981 · Cited by 34 · see citing works
Untranslated Region Sequences and the Efficacy of mRNA Vaccines against Tuberculosis
Reshetnikov, V., Terenin, I., Shepelkova, G., Yeremeev, V., Kolmykov, S., Nagornykh, M., Kolosova, E., Sokolova, T., Zaborova, O., Kukushkin, I., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25020888 · Cited by 33 · see citing works
A highly efficient human cell-free translation system
Aleksashin, N. A., Chang, S. T.-L., & Cate, J. H. D. (2023) · RNA · doi:10.1261/rna.079825.123 · Cited by 32 · see citing works
Xu, Y., Zheng, Y., Ding, X., Wang, C., Hua, B., Hong, S., Huang, X., Lin, J., Zhang, P., & Chen, W. (2023) · Drug Delivery · doi:10.1080/10717544.2023.2219870 · Cited by 31 · see citing works
Control of protein synthesis through mRNA pseudouridylation by dyskerin
Pederiva, C., Trevisan, D. M., Peirasmaki, D., Chen, S., Savage, S. A., Larsson, O. S., Ule, J., Baranello, L., Agostini, F., & Farnebo, M. (2023) · Science Advances · doi:10.1126/sciadv.adg1805 · Cited by 31 · see citing works
Advances in Nonviral mRNA Delivery Materials and Their Application as Vaccines for Melanoma Therapy
Neill, B., Romero, A. R., & Fenton, O. S. (2023) · ACS Applied Bio Materials · doi:10.1021/acsabm.3c00721 · Cited by 30 · see citing works
Considerations for mRNA Product Development, Regulation and Deployment Across the Lifecycle
Skerritt, J. H. (2025) · Vaccines · doi:10.3390/vaccines13050473 · Cited by 30 · see citing works
Ige, M. A., Ren, X., Yang, Y., Zhang, H., Shen, C., Jiang, Y., Li, J., & Wan, X. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102721 · Cited by 29 · see citing works
mRNA-based therapeutic strategies for cancer treatment
Taibi, T., Cheon, S., Perna, F., & Vu, L. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.04.035 · Cited by 28 · see citing works
Progress and Challenges in HIV-1 Vaccine Research: A Comprehensive Overview
Boomgarden, A. C., & Upadhyay, C. (2025) · Vaccines · doi:10.3390/vaccines13020148 · Cited by 28 · see citing works
Yang, L., Wang, T., Zhang, D., Huang, X., Dong, Y., Gao, W. Z., Ye, Y., Ren, K., Zhao, W., Qiao, H., et al. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202300935 · Cited by 28 · see citing works
Castellanos, M. M., Gressard, H., Li, X., Magagnoli, C., Moriconi, A., Stranges, D., Strodiot, L., Soto, M., Zwierzyna, M., & Campa, C. (2023) · Vaccines · doi:10.3390/vaccines11071153 · Cited by 28 · see citing works
Functions and therapeutic applications of pseudouridylation
Luo, N., Huang, Q., Zhang, M., & Yi, C. (2025) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-025-00852-1 · Cited by 27 · see citing works
Su, Y., Kim, T. T.-H., & Kim, B. (2024) · IEEE Journal of Solid-State Circuits · doi:10.1109/jssc.2024.3352907 · Cited by 26 · see citing works
mRNAid, an open-source platform for therapeutic mRNA design and optimization strategies
Vostrosablin, N., Lim, S., Gopal, P., Brazdilova, K., Parajuli, S., Wei, X., Gromek, A., Příhoda, D., Spale, M., Muždalo, A., et al. (2024) · NAR Genomics and Bioinformatics · doi:10.1093/nargab/lqae028 · Cited by 26 · see citing works
Chi, W.-Y., Hu, Y., Huang, H., Kuo, H., Lin, S., Kuo, C.-T. J., Tao, J., Fan, D., Huang, Y.-M., Wu, A. A., et al. (2024) · Journal of Biomedical Science · doi:10.1186/s12929-024-01082-x · Cited by 26 · see citing works
Lu, Y., Qian, C., Huang, Y., Ren, T., Xie, W., Xia, N., & Li, S. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.145501 · Cited by 26 · see citing works
RNA stability enhancers for durable base-modified mRNA therapeutics
Jung, S.-J., Seo, J. J., Lee, S., Hyun, S.-I., Lee, J.-E., Lee, S., Lee, Y., Chang, H., Lee, H., Kim, J.-H., et al. (2025) · Nature Biotechnology · doi:10.1038/s41587-025-02891-7 · Cited by 26 · see citing works
mRNA vaccines: immunogenicity and quality characteristics
Quan, Y., Yang, H., Li, W., & Li, L. X. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03800-5 · Cited by 26 · see citing works
- Authors
- Leppek, K., Byeon, G. W., Kladwang, W., Wayment-Steele, H. K., Kerr, C. H., Xu, A. F., Kim, D. S., Topkar, V. V., Choe, C., Rothschild, D., Tiu, G. C., Wellington-Oguri, R., Fujii, K., Sharma, E., Watkins, A. M., Nicol, J. J., Romano, J., Tunguz, B., Diaz, F., Cai, H., Guo, P., Wu, J., Meng, F., Shi, S., Participants, E., Dormitzer, P. R., Solórzano, A., Barna, M., & Das, R.
- Affiliations
- Stanford University (US)
- Eterna Massive Open Laboratory (US)
- Nvidia (United States) (US)
- Pfizer (United States) (US)
- Corresponding author
- Barna, Maria
- Das, Rhiju
- ORCID
- Leppek, Kathrin
- Byeon, Gun Woo
- Kladwang, Wipapat
- Wayment-Steele, Hannah K.
- Kerr, Craig H.
- Xu, Adele F.
- Kim, Do Soon
- Topkar, Ved V.
- Choe, Christian
- Rothschild, Daphna
- Tiu, Gerald C.
- Wellington-Oguri, Roger
- Fujii, Kotaro
- Sharma, Eesha
- Watkins, Andrew M.
- Romano, Jonathan
- Cai, Hui
- Guo, Pengbo
- Wu, Jiewei
- Meng, Fanyu
- Participants, Eterna
- Dormitzer, Philip R.
- Solórzano, Alicia
- Barna, Maria
- Das, Rhiju
- Venue
- Nature Communications
- Published
- 2022-03-22
- Volume
- 13
- Issue
- 1
- Pages
- 1536-1536
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC8020971
- OpenAlex
- W4220991830
- Cited by
- 399
- References
- 117
- Citations by year
- 2026: 88 · 2025: 127 · 2024: 99 · 2023: 53 · 2022: 23 · 2021: 8 · 2020: 1
- FWCI
- 24.66
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Nature Communications (publishedVersion, cc-by)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (submittedVersion, cc-by-nc)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- National Science Foundation
- Damon Runyon Cancer Research Foundation (DRG-2237-15)
- Pfizer
- Oregon State University
- Baidu
- National Institutes of Health
- University of California, San Francisco
- Stanford Bio-X
- Chemistry, Engineering and Medicine for Human Health, Stanford University
- Canadian Institutes of Health Research
- National Cancer Institute (R21CA219847)
- National Institute of General Medical Sciences (R35GM122579)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (F30HD100123, R01HD086634)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Research and Splicing
- Keywords
- mRNA stability, mRNA structure, mRNA vaccines, RNA therapeutics, protein expression, hydrolytic degradation, pseudouridine modification, mRNA design, COVID-19 vaccines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Claims read by deepseek-v4.1-flash under definition version 3 (extract-v3) on 2026-11-05.
Classified by jev-1.13-20260917 (gold-guideline-v0.2) on 2026-11-05.
Cited sources are checked by gpt-6-sol.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review